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ABSTRACT.
The ElB  deleted adenovirus, Onyx-015, has been shown to 
selectively replicate in and lyse cells with nonfunctional p53 (Bischoff et 
al,1996). This virus may be therapeutically useful in the treatment of a wide 
range of tumours since p53 abnormalities are very common in human 
cancer. The aims of this thesis were to develop an immunocompetent 
mouse model to study the role of the immune system in this form of 
therapy, to further examine the mechanism of selectivity of Onyx-015 for 
cells with non-functional p53, and lastly to determine whether or not Onyx- 
015 could increase the cytotoxicity to DNA damaging agents in functional 
and non-functional p53 cells.
We have shown that human adenoviruses will infect rodent cell 
lines but with variable infectivity. In tissues with high infectivity, 
productive virus infection only occurs in mouse epidermal cells but is 25 to 
50 fold less efficient compared to the human ovarian adenocarcinoma cell 
line A2780Cp70. The efficiency of replication in mouse epidermal cells is 
dependent on the expression of the early gene E lA  and this correlated with 
the expression of the nuclear factor cpAP3 , a transcriptional repressor of the 
ElA  promotor. Replication is shown to be 20 fold greater in squamous (well 
differentiated ) epidermal cell lines in which there is a high expression of 
ElA  and low cpAP3 expression compared to clonally related spindle (poorly 
differentiated) epidermal cell lines. Using mouse epidermal cell lines of 
known p53 status and function, the selective replication of Onyx-015 for 
cells with non-functional p53 is in general agreement with that reported in 
human cell lines . However, some cell lines with wild type p53 function do 
allow replication of Onyx-015 and we postulate that this is determined by 2 
factors, the expression of E lA  and the ability for Onyx-015 to repress p21 
levels. Using the squamous epidermal cell line PDVc57 , in-vivo studies in 
both nude mouse and syngeneic mouse tumour xenograft models showed 
decreased tumour growth with intratumoural virus injection compared to 
diluent injected tumours. However, viral replication is markedly reduced in
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the syngeneic host suggesting limitation of viral replication by the immune 
system.
Using the paired cell lines A2780 (functional p53) and the cisplatin 
resistant variant A2780Cp70 (non-functional p53) we have shown that 
replication is dependent on S-phase entry of the host infected cell and this 
correlated with E2F induction. In the cell line A2780, S phase entry and 
viral replication is limited due to virus induced p53 mediated apoptosis. We 
suggest that this is mediated by E lA  induction of p l9 " ^  . In contrast, 
A2780Cp70 allows a productive virus infection since apoptosis does not 
occur due to the absence of functional p53 and high expression of the anti- 
apoptotic factor ElB19kDa.
We have shown that in the cell line with nonfunctional p53 
(A2780Cp70) , cytotoxicity to both cisplatin and radiation is increased by 
preinfecting cells with Onyx-015. In the cell line with functional p53 
(A2780), preinfection with Onyx-015 for 72 hours also resulted in increased 
cytotoxicity to both cisplain and radiation. In contrast, preinfection of 
A2780 for 24 hours followed by cisplatin resulted in an antagonistic 
interaction leading to reduced drug sensitivity. It is suggested that this was 
due to p21 induction causing a reduction in the S-phase cell population.
Further in vivo and clinical studies investigating the role of the 
immune system in this form of therapy and in the use of combination 
therapies are therefore warranted.
CHAPTER 1 
INTRODUCTION
1.1. GENERAL INTRODUCTION.
p53 is the most important tumour suppressor gene and plays a central 
role in the negative regulation of the cell cycle. Mutations in the p53 gene are 
present in over 50% of all cancers ( Hollstein et al, 1991; Hollstein et al, 1996) 
and represent the single most important genetic alteration in human cancer. The 
incidence in individual cancers is 50% for colon, 40% for breast, 50% for lung, 
50-70% for head and neck. Mutation leads to loss of function of p53 and this is 
one mechanism for resistance to chemotherapy and radiotherapy ( Bergh et 
al,1995; Eliopoulos et al,1995). Therefore new effective therapies for tumours 
which lack functional p53 are needed. Gene replacement therapy, in which the 
p53 gene is reintroduced into tumour cells is one possible approach. The first 
clinical trial involving the réintroduction of p53 into tumours using a retroviral 
vector was carried out recently in patients with unresectable lung cancer (Roth 
et al,1996). This study showed that the therapy was safe but also produced 
regression of tumours in some patients. Another approach is to use therapies 
which selectively target cells which lack functional p53. The selectively 
replicating adenovirus, Onyx-015, has recently been shown to selectively 
replicate and lyse cells with non-functional p53 (Bischoff et al,1996). This 
virus is a chimeric human group C adenovirus formed from Ad2 and Ad5 
(Barker et al,1987). It has an 800bp deletion in the ElB region which codes for 
the 55kDa protein of ElB. The normal function of this protein is to bind to and 
inactivate the p53 protein in infected cells (Kao et al,1990). Because Onyx-015 
lacks this protein it is unable to replicate in cells with functional p53 since it 
cannot inactivate p53. However it will replicate effectively in cells with non­
functional p53 (Figure 1). Since over 50% of human tumours have p53
^ Ad2 infection of normal cell
4 ^  virus infects cell virus produces 53k viral replication
Adz has
/ b  1
*I  \  35k inactivates p33 WÊ
normal cell 
has functional
p33 ■
Onyx-015 infection of normal cell
virus cannot 
produce 33kvirus infects cell
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infection
p33 prevents viral 
replication
normal cell 
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virus infects cell virus can replicate
ElB gene
Onyx-013 has no
cancer cell
lacks p33
k cancer cell
cannot produce 
p33
• V
lysis
Figure 1. Schematic diagram showing the mechanism of 
action of the E lB 55kD a deleted adenovirus.Onyx-()15.
mutations, this virus may have an important therapeutic role in the treatment of 
a broad range of different cancers. Its main advantage lies in its ability to 
selectively destroy p53(-) tumours but leave surrounding normal tissue alone. 
Such targeted therapy at the molecular level cannot be achieved with 
conventional chemotherapy or radiotherapy. As such, phase I trials have begun 
in patients with pancreatic cancer, ovarian cancer and recurrent head and neck 
cancer. Results from the trial in patients with recurrent head and neck cancer 
are encouraging (Ganly et al,1997). In this study , 32 patients were treated with 
no significant toxicity and evidence of tumour necrosis occurred in some 
patients. However , despite these early results, several criticisms of this therapy 
have become evident.
Firstly, it was clear from the phase I trial that all patients treated 
developed a rising neutralising antibody to adenovirus after the first injection. 
The cell mediated response(Cytotoxic T lymphocytes) was not studied. We 
would expect that both the CTL and antibody responses to be detrimental to 
this therapy since the CTL response would cause the early elimination of virus 
limiting virus spread, and the antibody response would reduce the ability to 
reinfect host cells with adenovirus after the first inoculation. At present, there is 
no immunocompetent mouse model to test replicating adenoviruses since it is 
generally accepted that mouse tissue is not permissible to human adenoviruses. 
One of the aims of this thesis was to develop an immunocompetent mouse 
model by identifying a mouse tissue type which would support adenovirus 
replication . This would thus enable us to study the role of the immune system 
in this form of therapy and therefore potentially improve this type of therapy.
Secondly, several publications have disputed the p53 selectivity of the 
Onyx-015 virus. Goodrum and Ornelles,1997 showed that replication only 
occurred in cells which were in the S phase of the cell cycle and that this was 
independent of the p53 status of the cell lines studied. Hall et al,1998 recently 
suggested that adenovirus induced cell death was greater in cell lines which had 
wild type p53. Therefore another aim of this thesis was to further examine the 
mechanism of selectivity of Onyx-015 for p53(-) cells and to explain 
mechanistically any discrepancies to this selectivity.
Thirdly, most cancer therapies involve the use of multiple agents with 
different mechanisms of action in order to overcome any cellular resistance that 
tumour cells develop to any one particular cytotoxic agent. It is therefore 
unlikely that viral therapy with Onyx-015 would be efficacious as a single 
agent. We therefore wanted to determine whether or not combination therapy 
of Onyx-015 with chemotherapeutic agents or with radiation would be more 
effective than either agent alone and to explain any mechanistic interaction 
between these agents.
It is first necessary to describe the principles of cell cycle control and 
carcinogenesis, the role of p53 in human cancer , and the use of new forms of 
therapy such as gene therapy and adenovirus therapy in cancer therapy.
1.2. THE CELL CYCLE. ONCOGENES AND TUMOUR SUPPRESSOR 
GENES.
The cell cycle consists of 4 phases - S phase during which DNA 
synthesis occurs, M phase during which mitosis occurs, and temporal gaps in
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between these two events termed G1 and G2 during which time the molecules 
required for DNA synthesis and mitosis are synthesised.
Between each of these phases there are checkpoints which are 
controlled by genes which switch on the cell cycle (e.g. Ras oncogene, myc 
oncogene) and genes which switch off the cell cycle (e.g. p53, p l6  tumour 
suppressor genes). These genes act at the checkpoint through a family of 
protein kinases, called cyclin dependent kinases (cdks) (Pines et al, 1993). All 
the cdks require associated cyclin proteins for activity. The Gl/S checkpoint is 
controlled by complexes between cdk4 and Cyclin D and cdk6 and Cyclin D 
(Sherr, 1993). Cyclin E in association with cdk2 is required for Gl/S transition 
(Knoblich and Lehner, 1993) and cyclin A, in complex with cdk2 is essential 
for progression through S phase (Reviewed in Fisher, R. P. 1997). Both A and 
B type cyclins associate with cdc2 to promote entry into mitosis at the G2/M 
checkpoint (Knoblish et al, 1993).
At the Gl/S checkpoint, the phosphorylation status of the Rb gene 
determines S phase entry (Weinberg,1995 for review). In its active form, Rb 
exists in a hypophosphorylated form complexed to the transcription factor E2F. 
When it is phosphorylated into the hyperphosphorylated form by either 
cdk4/cyclinD or cdk6/cyclin D, it becomes inactive and releases the E2F factor. 
E2F then activates genes essential for DNA replication such as dihydrofolate 
reductase (DHFR) (Slansky et al,1993), DNA polymerase a, thymidine kinase, 
thymidylate synthase (Johnson et al,1994) by binding to E2F sites in the 
promoters of these genes. This therefore allows S phase entry to occur( Hinds 
and Weinberg, 1994). (Figure 2)
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Figure 2. Diagram showing control o f Rb phosphorylation and S phase entry.
S phase entiy requires phosphoiiation of Rb which causes release of E2F. 
Phosphorylation of Rb is by cyclin dependent kinases CDK4 and CDK6. These kinases 
are activated by Cyclins such as CyclinD and aie inactivated by inhibitors p l6  and 
p21(cdk inhibitors).
Cdk4 and cdk6 can be inactivated by cdk inhibitors. The 2 most 
important cdk inhibitors are p l6  and p21. Thus, loss of either p l6  or p21 
causes activation of cdk4 and cdk6 and therefore phosphorylation of Rb 
causing S phase entry. pl6 is a tumour suppressor gene and is frequently 
inactivated in tumours, particularly squamous cell cancer of the head and neck 
(Reed et al,1996). In addition, the main factor controlling p21 expression is 
p53. Mutation of p53 leads to loss of transcriptional activity causing loss of 
transcriptional activation of p21. This leads to activation of the cdk4/6 and S 
phase entry.
1.3. P53 AND HUMAN CANCER.
1.3.1.Molecular Structure of p53.
a) Domains ofp53.
The p53 gene is located on chromosome 17p.21 and codes for a 393 
amino acid nuclear phosphoprotein. p53 was originally discovered as a protein 
complexed to SV40 T antigen in SV40 transformed cells (Lane and Crawford, 
1979). Its structure can be divided into 3 domains - the transcriptional 
activation domain at the N terminus, the sequence specific DNA binding 
domain in the centre, and the oligomerisation domain at the C terminus. There 
are 5 conserved regions (conserved through evolution) , 4 of which are located 
in the DNA binding domain.(Figure 3)
p53 is present predominantly as tetramers through the oligomerisation 
domain (Cho et al,1994; Jeffrey et al,1995). Dimers and monomers account for 
less than 5% of the total p53 molecules in a cell. The sequence specific DNA 
binding domain (Pavletich et al, 1993; Wang et al,1993) is very important as
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p53 regulates transcription through this region. p53 binds specifically to a p53 
responsive element that contains repeats of the consensus binding sequence Pu- 
Pu-Pu-C-A/T-T/A-G-Py-Py-Py where Pu and Py are purine and pyrimidine 
nucleotides respectively (El-Deiry et al,1992).The N terminus of p53 is the 
transcriptional activation domain. This region can transcriptionally activate or 
repress other genes. p53 acts as a transcriptional activator of mdm2, box, IGF- 
BP3, p21,GADD45, Cyclin G, Thrombospondin (Dameron et al, 1994) and acts 
as a transcriptional repressor for the genes PCNA (Proliferating Cell Nuclear 
Antigen), c-fos ,c-jun, IL-6 and bcl2 (Horikoshi et al, 1995).
b) Phosphorylation o f  p53.
p53 protein is extensively post-translationally modified, mostly by 
phosphorylation and this is important in regulation of p53 
function(Meek,1994). p53 is phosphorylated at sites within its N terminal and 
C terminal regions by several protein kinases. One such kinase is the double 
stranded DNA dependent protein kinase , DNA-PK(Lees-Miller et al, 1990). It 
is a nuclear serine/threonine protein kinase. Activation of DNA-PK requires 
DNA double strand breaks or other discontinuities in DNA (Gottlieo et 
al,1993). DNA-PK phosphorylates human p53 at serines 15 and 37(Lees- 
Miller,1992). The DNA-PK phosphorylation sites are localised within the 
transcriptional activation domain of p53. These sites also interact with 
transcription factors such as the TAFs and cellular coactivators p300/CBP (Lill 
et al,1997). These phosphorylation sites are also located next to the region 
where p53 binds to mdm2 (Kussie et al,1996). Recently it was shown that 
DNA damage induces phosphorylation of p53 at serine 15 via DNA-PK and
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that this results in the disruption of the p53/mdm2 interaction (Shieh et 
al,1997) thus alleviating mdm2 inhibition of p53. Phosphorylation of serine 15 
of p53 in response to DNA damage from ionising radiation has also recently 
been shown to occur by the ATM (Ataxia telangectasia) protein (Banin et 
al,1998; Canman et al,1998).
Relatively little is known about the enzymes which catalyse the 
dephosphorylation of p53 in vivo. However protein phosphatase 2A has been 
shown to dephosphorylate several phosphorylated sites on p53 in vitro ( 
Scheidmann, et al 1991).
1.3.2. Activation of p53.
p53 is activated by DNA damaging agents such as ionising radiation 
and cytotoxics, hypoxia and UV light (Kastan et al, 1991). DNA damage from 
ionising radiation causes p53 protein levels to rise in cells with an increase in 
transcriptional activity (Kastan et al,1992; Kuerbitz et al, 1992). Ionising 
radiation causes DNA damage by causing strand breaks in the DNA and these 
strand breaks signal p53 activation (Hartwell et al, 1989). It has been 
suggested that as little as one double strand break per cell can initiate the p53 
pathway (Huang et al 1996). It has recently been shown that activation of p53 
in response to DNA damage involves phosphorylation of p53 at serine 15 
causing a conformational change in p53. This phosphorylation involves kinases 
including DNAPK (Shieh et al,1997) and ATM (Banin et al,1998; Canman et 
al,1998) as described above.
Exposure of cells to hypoxic conditions results in increased p53 protein 
levels and can lead to p53 dependent apoptosis (Graeber et al, 1996). It is
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widely believed that this induction of p53 occurs in the absence of DNA strand 
breaks. It has been shown that depletion of ribonucleotide triphosphates 
(rNTP) using inhibitors of purine and pyrimidine biosynthesis, is sufficient to 
induce p53 and p53 dependent G1 arrest (Linke, et al 1996). It may be the 
case that an inadequate supply of rNTPs results in changes in the RNA 
macromolecule population, analogous to the way that dNTP inhibitors lead to 
DNA strand beaks.
1.3.3. Normal function of p53.
p53 is the most important tumour suppressor gene and plays a central 
role in the negative regulation of the cell cycle (Lane,1992; Levine,1997 for 
review). In response to DNA damage or foreign DNA synthesis, wild type p53 
is stimulated causing either a G1 arrest or apoptosis of the cells. Figure 4 
shows a schematic diagram of p53 activation and p53 dependent G1 arrest and 
apoptosis.
a) G1 arrest.
Ionising radiation induced DNA damage can result in a G1 arrest which 
is mediated mainly by the p21 protein (El-Diery et al, 1993; Harper el al 1993). 
p21 mRNA levels, as well as protein levels, increase following exposure of 
cells to ionising radiation in a p53 dependent manner (Xiong et al, 1993). p21 
causes a G1 arrest by acting as a cyclin dependent kinase inhibitor preventing 
the phosphorylation of the Retinoblastoma gene product (pRb). In addition, 
p21 causes G1 arrest by inhibiting PCNA(proliferating cell nuclear antigen) ,a 
36kDa protein capable of interacting with DNA polymerase a  and which 
normally stimulates DNA replication and repair (Luo et al, 1995 ). The binding
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of p21 to PCNA does not affect the DNA repair activity of PCNA but is 
thought to alter the availability of PCNA for DNA replication. p21 is the most 
important mediator of p53 dependent cell cycle arrest. However other genes 
transcriptionally activated by p53 may play a role in DNA damage arrest. These 
include Cyclin G (Okamoto et al, 1996) and GADD45 (Kastan et al, 1992). 
Like p21, GADD45 also contains a p53 binding site and has been shown to be 
induced by p53 (Lu et al, 1993). 
b) Apoptosis.
Apoptosis, or programmed cell death, is the process by which a cell 
actively commits suicide under a tightly controlled cascade of events. 
Apoptosis is recognisable microscopically by characteristic condensed 
basophilic cytoplasm, darkly staining nuclei, and the presence of apoptotic cell 
bodies. DNA from cells undergoing apoptosis is cleaved into fragments of 
roughly 200 base pairs. The signals that trigger apoptosis include the presence 
of DNA damage, growth factor or nutrient withdrawal, disruption of cell matrix 
interactions, altered expression of potent cellular oncogenes such as myc, and 
viral infection.
Apoptosis is controlled by the Bcl2 group of proteins which include the 
apoptotic factors bax (Oltavi et al 1993) , bak and bclxs (Boise et al, 1993) and 
the antiapoptotic (survival) factors Bcl2 , bad and bclxL. Bcl2 protein is an 
intracellular membrane protein that resides in the outer mitochondrial 
membrane, nuclear envelope and parts of the endoplasmic reticulum. The 
protein has been shown to block cell death induced by numerous stimuli
including growth factor deprivation, Ca^^ ionophores, reactive oxygen species, 
some viruses, heat shock, and irradiation (Reviewed in White 1997).
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p53 can transactivate bax (Selvakumaran et al, 1994) which contrasts 
with its ability to repress transcription of Bcl2. (Miyashita et al, 1994) Thus in 
response to DNA damage, p53 is activated causing activation of bax and 
repression of Bcl2. It has been proposed that when Bcl2 is in excess, Bcl2 
homodimers predominate and cells are protected and when bax is in excess, 
bax homodimers predominate and cells are susceptible to apoptosis (Oltavi et 
al, 1993). (Figure 5)
Although bax is the main mediator of apoptosis, the insulin-like growth 
factor binding protein 3 gene (IGF-BP3) may also be important in apoptosis 
(Buckbinder et al, 1995). IGF-BP3 protein has the ability to inhibit the 
signalling of insulin- like growth factor receptors and so plays an antimitogenic 
role in the cell. It can cause both G1 arrest and also apoptosis.
1.3.4. Regulation and stabilisation of p53.
p53 levels are controlled by the protein mdm2 (Barak et al, 1993). This 
protein has the ability to complex with p53 and inhibit its transcriptional 
activity. Mdm2 is transcriptionally activated by wild type p53 in response to 
DNA damage. Thus an auto regulatory feedback loop exists between mdm2 
and p53. Overexpression of mdm2 inhibits p53 dependent G1 arrest in 
response to irradiation (Barak et al, 1993; Perry et al, 1993). It has been shown 
that mdm2 also promotes the degradation of p53. This is thought to be an 
important mechanism in ensuring that the p53 signal is quickly terminated 
(Haupt, et al 1997).
All mutant p53 proteins are degraded in the presence of mdm2. It has 
been suggested that mutant p53 proteins have a longer half-life than wild type
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because they are not degraded (Midgley et al,1997). This is because mutant 
p53 is non-functional and is therefore not capable of transcriptionally activating 
mdm2 leading to less mdm2 mediated degradation.
In response to DNA damage, p53 levels increase leading to increased 
transcription of mdm2. The auto regulatory feedback loop between mdm2 and 
p53 would then lead to the early degradation of p53 and loss of p53 
transcriptional activity. This is undesirable in a situation of DNA damage 
where prolongation of p53 transcriptional activity is required. Shieh et al,1997 
showed recently that after DNA damage, N terminal phosphorylation of p53 
occurs by DNA-PK at serine 15 and this disrupts the p53/mdm2 interaction. 
Thus p53 is stabilised and transcriptional activity is prolonged. Another factor, 
pl9^^-INK4a, has been reported to promote mdm2 degradation and therefore 
stabilise p53 (Zhang et al,1998; Pomerantz et al,1998). This mechanism of 
regulating p53 activity is distinct from that involving DNA damage since no 
phosphorylation of p53 occurs. It has been shown that oncogenes such as the 
adenoviral E lA  and Myc regulate p53 dependent apoptosis by the induction of 
pjqARF ^2indy et al,1998; de Stanchina et al,1998). A schematic diagram 
showing the regulation of p53 is shown below.
Oncogenes DNA damage
(ElA, (IR,UV,drugs)
pj9ARF Kinases(DNAPK, ATM)
p53
Cell cycle arrest 
or qx)ptosis
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1.3.5. Mutation of p53.
The most common somatic mutations in p53 are single base 
substitutions (point mutations) in the conserved regions of the gene i.e. exons 
5-8 (Hollstein et al, 1991) (Figure 3). Most point mutations result in missense 
mutations which cause a change in a single amino acid. However a few result 
in frameshifts and premature termination of translation (Stop codons). These 
mutations are termed nonsense mutations. As well as single base substitutions, 
complete or partial deletions can also occur but these are not common. As a 
consequence of mutation, mutated p53 cannot bind or regulate transcription 
through the specific DNA binding sequence. Therefore cells which sustain 
DNA damage are unable to respond by p53 mediated G1 arrest or apoptosis. 
Damaged DNA is retained leading to cellular transformation, genomic 
instability (Smith et al,1995) and the malignant phenotype. Germline mutations 
in p53 can also occur. Li-Fraumeni syndrome (LFS) is a rare autosomal 
dominant condition (Malkin et al,1990) in which patients are born with 1 
mutated p53 allele and 1 wild type p53 allele. Mutation of the normal allele by 
somatic mutation results in p53 inactivation.These patients develop sarcomas 
in childhood (bone,soft tissues) and more rarely brain,lung, adrenocortical and 
bone marrow tumours.
1.3.6. Inactivation of p53.
As well as mutation and deletions, p53 may be inactivated by binding 
to cellular or viral proteins. The cellular factor mdm2 inhibits the 
transcriptional activity of p53 as previously described. Amplification or 
overexpression of mdm2 can therefore cause p53 inactivation mimicking p53
19
mutation . The mdm2 gene is frequently amplified in sarcomas‘(Oliner et al,
1992). Viral oncoproteins can also inactivate p53. Adenoviral ElB (55kDa) 
(Kao et al, 1990; Debbas et al, 1993; Sarnow et al, 1982) , HPV E6 (Lechner et 
al, 1992; Scheffner et al, 1990), and SV40 large T antigen (Gannon et al, 1987) 
all bind to p53 causing inactivation of the p53 protein. The same viruses also 
inactivate the other tumour suppressor gene Rb (retinoblastoma) by other viral 
proteins such as adenoviral E lA  (Levine et al,1990), HPV E7 (Dyson et 
al,1989) and SV40 large T (Levine et al,1990).
1.3.7. Clinical importance of p53 inactivation.
p53 dependent apoptosis is one of the main mechanisms of cell death of 
many cytotoxic agents. Thus loss of p53 function results in reduced sensitivity 
to chemotherapy (Lowe et al,1993; Lowe et al,1994; Eliopoulos et al,1995) and 
radiotherapy (Lowe and Schmitt,1993). p53 inactivation is also correlated with 
poor prognosis and disease progression (Lowe et al,1994). Therefore p53 
inactivation is very important clinically . Because of this, new agents which 
either restore p53 function or which selectively target cells which lack p53 are 
being developed. Such genetic based therapy represents an area which is 
rapidly expanding in cancer therapy. Indeed restoration of p53 function has 
recently been carried out in p53(-) lung cancer patients by bronchoscopic 
injection of a retroviral vector with the wild type p53 transgene (Roth et 
al,1996). This resulted in apoptosis in tumours causing regression of tumours in 
some patients.
20
1.4. GENE THERAPY.
1.4.1. Principles of gene therapy ( Tolstoshev and Anderson ,1995 for 
review).
Gene therapy involves the introduction of foreign DNA into somatic 
cells to produce a therapeutic effect (Fujiwara and Roth,1994 for review). The 
therapeutic gene is transferred into the tumour cells using a vector. Transfer 
may either be in-vivo in which the DNA and vector are directly introduced into 
the body, or ex-vivo in which cells are removed from the body, transfected with 
DNA and then reintroduced into the patient. Figure 6.
1.4.2. Gene delivery systems.
The mode of gene transfer can be classified into chemical, physical and 
viral. In chemical transfection, DNA can be introduced into cells using calcium 
phosphate, liposomes or DNA/protein complexes. Although useful for 
laboratory transfections, these are inefficient in vivo due to their poor 
efficiency of transfection. In addition , liposomes and protein/DNA complexes 
are rapidly cleared from the body via the immune system. Physical methods of 
DNA transfection are by electroporation, microinjection and the use of ballistic 
particles. Electroporation guns for the introduction of chemotherapeutics, as 
well as genes, are currently being tested in various cancers. In addition, guns 
which fire small gold particles coated with DNA have recently been developed 
and are being tested. However, the most important method of transfer of DNA 
currently being used is viral vectors.
Viruses used include retroviruses, adenoviruses, adeno-associated 
viruses and herpes viruses. Retroviruses contain RNA genomes that are reverse
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Figure 6.
Schematic diagram illustrating in vivo and ex vivo 
gene transfer.
transcribed after introduction to produce a double stranded cDNA. This 
integrates stably and heritably into random sites of the host genome. These 
viruses give a high efficiency of transfer. The host range of cells which they 
infect includes fibroblasts, epithelial cells and smooth muscle cells. Cells of 
lymphoid origin are more resistant. They give permanent gene expression 
which is advantageous in situations where long term expression of the 
transgene is required. This is the case in inherited conditions such as cystic 
fibrosis. They are currently limited due to the low production titre that can be 
produced pfu) which reduces transduction efficiency into solid
tumours. Other disadvantages are that they only infect dividing cells and that 
the stable random integration into the host genome may be dangerous if germ 
cell transfection occurs. They are also limited in the size of transgene which 
can be inserted (~7-8kb). Therefore, the use of retroviruses has recently been 
superceded by the use of adenoviral vectors (Wilson et al,1996; 
Ginsberg,1996).
Adenoviruses are double stranded DNA viruses. They can be made 
replication defective with deletion of the E l and E3 regions of their genome. 
The transgene can then be introduced into the vacated site. Because they have a 
larger genome than retroviruses they can carry larger transgenes up to 36 kb 
DNA. They have a tropism for a broader range of cell types and because they 
can be produced at high titres (~10^^pfu) they have a higher transduction 
efficiency. Another advantage is that they can infect both nondividing as well 
as dividing cells. There is no integration into the host cell genome and therefore 
only transient gene expression occurs, usually lasting for 7-42 days. This is 
adequate for cancer therapy but would not be desired in situations where long
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term gene expression is required. Other disadvantages are that they continue to 
express other viral gene products which are recognised by the immune system 
leading to an inflammatory response and short term gene expression, they may 
become replication competent by genetic recombination, and because 90% of 
humans have antibodies to human adenoviruses pre-existing immunity may 
reduce the transduction efficiency to very low levels particularly on second 
exposure to the adenoviral vector.
1.4.3. Classification of cancer gene therapy.
There are 4 main types of genes which can be introduced into tumour 
cells.These are
1. genes which suppress the expression of an oncogene i.e. anti-oncogenes.
2. genes which restore a defective tumour suppressor gene (replacement gene 
therapy).
3. genes which enhance immune surveillance ( immunotherapy).
4. genes which activate prodrugs into active chemotherapeutic agents (gene 
directed enzyme prodrug therapy i.e. GDEPT).
1.4.4. Tumour suppressor gene replacement therapy.
There is currently one approved trial for tumour suppressor gene 
therapy ( Clayman et al,1998). This utilises a replication deficient adenovirus 
for the transmission and overexpression of a wild type p53 gene. The 
hypothesis is that the wild type p53 gene would be dominant over its mutant 
gene and select against proliferation and induce a p53 mediated apoptosis 
(Neilson et al,1998). In-vitro and in-vivo studies using such a technique have
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demonstrated growth suppression in a variety of cell types ( Liu et al ,1995; 
Clayman et al, 1995; Ko et al,1996). Phase I/II trials are underway at the MD 
Anderson Cancer Center, Texas,USA in patients with advanced cancer of the 
head and neck and in patients with unresectable lung cancer.
1.4.5. Immunotherapy.
In immunotherapy, the aim is to either increase the immunogenicity of 
the tumour (Townsend et al, 1993) or increase the effectiveness of tumour 
infiltrating lymphocytes (Rosenberg et al, 1991). The immunogenicity of the 
tumour can be increased by transfecting into the tumour cells MHC class I and 
II genes to increase antigen presentation (Plautz et al,1993). Nabel et al,1993 
reported the reduction of tumour size in a melanoma patient after gene transfer 
of MHC class I gene. The presence of antigen and MHC alone are insufficient 
for immune induction , and a class of molecules called costimulatory molecules 
are also required. These are expressed on antigen presenting cells and the best 
studied are called B7-1 and B7-2. If B7 is transfected into tumour cells then 
this should provide the necessary costimulation required for immune 
stimulation. Chen et al ,1994 showed that B7 transduction by a retroviral vector 
decreased the tumourgenicity and induced protective immunity .
The effectiveness of tumour infiltrating lymphocytes can be improved 
by cytokines interleukins 2 and 4 (Lin et al,1993), tumour necrosis factor , 
interferon alpha and gamma, and granulocyte-macrophage colony stimulating 
factor. Again clinical trials are underway.
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1.4.6. GDEPT.
Adenovirus mediated gene transfer of the herpes simplex virus 
thymidine kinase gene has shown a reduced growth of squamous cell cancer in 
a nude mouse model (O’Malley BW Jr et al, 1995; O’Malley BW Jr et al, 
1993) and also in lung (Esandi et al,1997), brain (Quillren et al,1997), prostate 
tumours. Herpes simplex virus thymidine kinase renders cells sensitive to the 
nucleoside analogue gancyclovir by converting gancyclovir into an active 
phosphorylated compound that terminates DNA synthesis. Thus tumour cells 
transduced with the gene will be killed when exposed to gancyclovir. The 
antitumour effect is dependent upon a biochemical bystander effect which is 
mediated by gap junctions between cells (Elshami et al,1996). The toxic 
metabolite is able to pass from a transduced cell into a nontransduced cell via 
gap junctions. Therefore only 10-20% of tumour cell transduction is required 
for efficacy. Other prodrug activating systems include the enzyme cytosine 
deaminase which converts the prodrug 5-flurocytosine to 5-flurouracil and the 
enzyme nitroreductase which converts the prodrug CB1954 into an active 
alkylating agent (Bridgewater et al,1997). Unlike HSVtk/gancyclovir, the 
active metabolite in these two systems is able to diffuse across cell membranes. 
Therefore the bystander effect is not dependent on gap junctions in these 
systems. Further selectivity can be achieved in GDEPT if the prodrug 
activating enzyme gene is linked to a tissue specific promoter. The gene erbB-2 
is present in -80% of pancreatic cancers and this is useful in GDEPT therapy 
since this promoter can be linked to the HSVtk gene to produce tissue 
selectivity (Ring et al,1997). This is the current area of research which is being 
explored in GDEPT at present.
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1.5. HUMAN ADENOVIRIDAE.
1.5.1.Morphology and genome stucture.
There are 42 human serotypes. The first human adenoviruses were 
discovered by Rowe et al (1953) and Hilleman and Werner (1954) and are now 
classified into 6 subgroups, A-F, based on immunological, biological, 
morphological and biochemical criteria. They cause a number of diseases in 
humans including respiratory, ocular, urinary and gastrointestinal diseases and 
are important human pathogens, although they are not often associated with 
fatal diseases (White and Fenner,1986; Horwitz,1990).
a) Morphology.
Adenoviruses are non-enveloped icosahedral particles containing linear 
double stranded DNA and a protein capsid. The capsid consists of 252 
capsomers (Horne et al,1959). Fentons lie at the 12 vertices and 240 hexons 
form the facets for each capsomere. Hexons contain 3 identical protein chains ( 
protein II). This hexon trimer has a triangular top superimposed on a 
pseudohexagonal base. Hexons carry type, group, intrasubgroup and 
intersubgroup antigenic determinants (Norrby and Wadell,1969). Fentons 
consist of penton base and filamentous projections, the fibres. The penton base 
is a pentamer of protein III and the fibre is a trimer of protein IV (Van Oostrum 
and Burnett,1985).The fibre contains the sites responsible for interaction of the 
virus with cellular receptors (Fhilipson,1967).
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b) Genome structure.
The adenovirus genome is a double stranded linear DNA molecule. The 
entire DNA sequence of Ad2 is known and is 35,937 nucleotides long. Gene 
expression can be divided into early and late phase, separated by the onset of 
DNA replication. Transcription is initiated from a number of promoters at early 
and intermediate times. All the late genes are transcribed from the same 
promoter, the major late promoter (MLP) (Gelinas and Roberts,1977).
1.5.2. The Lytic Cycle.
a) Virus entry into cells.
Adenoviruses bind to cells by the fibre capsid protein. The cellular 
receptor was recently discovered (Bergelson et al,1997; Bergelson et al,1998; 
Tomko et al,1997) and is called CAR (Coxsackie adenovirus receptor) as it is 
also the same receptor for coxsackie virus infection. This is followed by 
endosome-mediated internalisation of the virion via interaction between the 
penton capsid protein and «vpg and QvPs integrins ( Wickham et al,1993). The 
virion is disassembled and extruded by lysis of the endosome and then the 
DNA-protein core enters the nucleus through nuclear pores ( Greber et al,
1993).
b) Transcription
In the nucleus, the adenovirus genes are transcribed by the host DNA 
polymerase II. The immediate-early ElA  proteins are expressed, and then they 
induce transcription of the delayed-early genes in the ElB, E2, E3, E4 and LI 
(early) transcription units. Each of these early regions contains its own 
promoter (Berk and Sharp,1977a). These early proteins convert the cell into an
27
efficient factory for virus replication and counteract host antiviral defences. 
Viral DNA replication occurs at 7 hours postinfection. Finally, after the onset 
of DNA replication, the late genes (L1-L5) are transcribed. These late 
transcripts are processed from a common nuclear precursor RNA which is 
initiated from the major late promoter (MLP) (Ziff and Evans,1978).In this late 
phase we get the expression of virion proteins and proteins required for 
assembly of infectious virions. In addition the synthesis of cellular DNA, 
mRNA, protein is inhibited. Virions then assemble in the cell nucleus 1 day 
post infection and increase in number until 2-3 days post infection. They are 
then released from the cell.
c) Assembly o f virions.
The initial step is the formation of capsomers, hexon, penton base and 
fibre, from their monomeric forms in the cytoplasm and the assembly of empty 
capsids. Viral DNA and core proteins are then inserted into the capsid 
(Philipson,1984). The LI 52/55kDa proteins have been shown to be required 
for virion assembly.
d) Cell lysis and release o f  virions.
The mechanism of cell lysis is not well understood. The L3 encoded 
protease cleaves cytokeratin, disrupting the cytokeratin network, rendering the 
cell susceptible to lysis (Chen et al,1993). This is enhanced by inhibition of 
host protein synthesis which prevents repair of the cytokeratin network (Zhang 
et al,1994). In addition, the E3 11.6kDa adenoviral death protein promotes cell 
lysis (Tollefson et al,1996) possibly by inhibiting the apoptotic factors Bcl2 and 
ElB 19kDa at the nuclear membrane or possibly by forming channels for e.g. 
Ca^ "^  ions.
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1.5.3. Early region lA
a) E lA  transcription
The ElA  DNA sequence is known for many serotypes and comparison 
shows 3 conserved domains termed CRT, CRII, CRIII ( Moran and 
Mathews,1987). These domains determine the function of the E lA  proteins. 
There are 5 mRNA species, 3 major termed 13S,12S and 9S and 2 minor 
termed IIS  and 1 OS .The sizes of the mRNAs are shown in Figure 7. The 12S 
and 138 mRNAs are translated in the same reading frame but their products 
differ by a block of 46 aminoacids found only in the 138 product. This region is 
the CRIII domain found only in 138. The ElA  promoter consists of a TATA 
box and an ATE binding site.
The E lA  region is the first region to be transcribed during viral 
infection (Nevins et al, 1979). The level of the 128 and 138 proteins in the 
cytoplasm peaks at 5 hours post infection and then declines through 12 hours 
post infection (Glenn and Ricciardi, 1988).The levels of the 98, 108 and 118 
proteins accumulates in the cytoplasm late in infection (8tephens and 
Harlow,1987).
b) E lA  protein products.
ElA  proteins are phosphoproteins predominantly localised in the 
nucleus of infected cells (8chmitt et al,1987). 8pecific functions have been 
assigned to 3 regions within E lA  which are well conserved between different 
serotypes. CRI is present in the 289aa 138 protein and the 243aa 128 protein 
and is required for transcriptional repression, transformation and induction of 
DNA synthesis ( Lillie et al,1987). CRII is present in all but the smallest E lA  
proteins and is required for transformation ( Lillie et al,1986; Moran et
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Figure?. Diagram of E lA  m RNA’s
Inti ons occur where the lines peak upward. Conserved domains are 
indicated as 1,11 and 111. The 2 most im portant mRNAs are the 12S 
and 13S. These differ only in the C R lll domain which is absent in the 
12S mRNA.
al,1986a) as well as induction of DNA synthesis (Howe et al,1986). CRIII is 
unique to the 289aa 13S protein and is essential for the transactivating function 
of E lA  (Moran et al, 1986b; Lillie et al,1987).
c) Transactivation function o f  E lA .
The CRIII region is able to transactivate the ElB, E2, E3, E4 and the 
LI (early) transcription units. The mechanism of E lA  transactivation appears to 
be indirect, not involving an interaction between ElA  proteins and specific 
DNA sequences within the activated promoter, but through cellular 
components. It activates the ElB, E2, E3, MLP(major late promoter) via a 
TATA box thus implicating the TATA transcription factor (TFIID) in the 
process (Wu et al, 1987; Manohar et al,1990; Garcia et al, 1987; Nevins et 
al,1981). The E2 promoter also has two binding sites for E2F and E lA  
regulates the E2 promoter mainly through E2F rather than TFIID. The binding 
of two E2F molecules to their binding sites is assisted by the 19.5kDa E4orf6/7 
protein which binds E2F (Huang and Hearing et al,1989a; Reichel et al,1989).
The E4 promoter has ATF binding sites which are activated by E lA  . 
This regulation is via ATF factors, a factor termed EIVF, and E4F.
d) Transcriptional repression by E lA .
E lA  protein products can repress transcription of viral or cellular 
enhancer sequences ( Borelli et al,1984; Hen et al,1985; Velich and Ziff,1985; 
Hen et al,1986; Stein and Whelan,1989). Sequences within the CRI region are 
essential for repression ( Lillie et al,1987; Jelsma et al,1989; Stein et al,1990).
e) Oncogenic transformation by E lA .
ElA  proteins can immortalise primary rodent cells in culture and 
cooperate with other oncogenes, such as the ElB gene products or an activated
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ras gene, to produce fully transformed cells. They do this by inactivating 
proteins Rb, pl07 and p300 ( Yee and Branton,1985; Harlow et al,1986). The 
Rb protein complexes to E lA  causing release of E2F transcription factor from 
the Rb/E2F complex (Shenk and Flint,1991). This leads to S phase entry in the 
cell cycle as discussed before. Another domain of E lA  binds to the 
transcriptional coactivator p300 (Samuelson and Lowe,1997). Binding of both 
E lA  domains to Rb and p300 is required for transformation (Shenk and 
Flint,1991).
1.5.4. Early region IB
a) General organisation o f the E lB  region.
The ElB region is located immediately downstream of the E lA  region. 
The ElB sequence is known for many serotypes ( e.g. Ad2,Gingeras et 
al,1982; Ad5,Bos et al, 1981) and there is considerable sequence homology 
between serotypes. The 2 major transcripts are 22S and 13S . There are 2 minor 
species at 14S and 14.5S. The 2 major proteins are a 19kDa protein , encoded 
by the first open reading frame (ORE), and a 55kDa protein encoded by the 
second ORF ( Bos et al,1981; Anderson et al, 1984).
b) E lB  transcription.
ElB gene expression is controlled in a complex manner. The 22S 
mRNA accumulates first in the cytoplasm at 3.5-9hrs post infection, while the 
13 S mRNA remains low until 8 hrs post infection rising to a level comparable 
to the 22S mRNA at 12 hrs post infection (Glenn and Ricciardi,1988).
c) The E lB  promoter.
The ElB promoter is activated by ElA. It consists of a TATA box and a 
binding site for the cellular transcription factor Spl (Wu et al,1987). These
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elements are conserved in all adenovirus serotypes. E lA  transactivation of ElB 
is mediated through the TATA box and is not affected by Spl binding. It does 
this by increasing the expression of the TATA binding factor TFIID.
d) The 19kDa protein.
This protein is important for viral infection as it inhibits E lA  mediated 
apoptosis by inactivating the proapoptotic bax protein (Han and White,1996 for 
review). This is because the ElB 19kDa protein is homologous to the survival 
factor Bcl2. In addition, it prevents E lA  induced cytolysis by Tumour necrosis 
factor (TNF), an inflammatory cytokine secreted by activated macrophages 
(White et al,1992).
e) The 55kDa protein.
The 55kDa protein is translated from the 22S mRNA ( Bos et al, 1981; 
Anderson et al,1984). The 55kDa protein acts within the nucleus by increasing 
the stability of late viral mRNA and transporting it from the nucleus to the 
cytoplasm. It does this in a complex with the E40RF6 protein (Ornelles and 
Shenk,1991).
Transformation by viral infection requires the entire E l region 
including the 55kDa protein (Babiss et al,1984; Barker and Berk,1987; Byrd et 
al,1988). The role of the 55kDa protein in transformation is due to its 
interaction with the cellular protein p53 (Sarnow et al,1982b). It binds directly 
to the N terminus of the p53 tumour suppressor gene and causes transcriptional 
inactivation of p53 ( Dobner and Shenk et al,1996; Teodoro et al,1997). In 
addition, E lB  55kDa also mediates the degradation of p53. This degradation of 
p53 is believed to be mediated by complex formation between p53, E lB  and
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E40RF6 (Dobner and Shenk ,1996; Steeganga et al,1997) which targets p53 
for degradation via the ubiquitin degradation pathway.
1.5.5. The selectively replicating adenovirus, Onyx-015, as an anticancer 
agent.
The ElB deficient adenovirus, Onyx-015, has recently been shown to 
selectively replicate in and lyse p53(-) tumour cells both in vitro and in vivo 
(Bischoff et al,1996; Heise et al, 1997). This virus is a chimeric human group C 
adenovirus (Ad2 and Ad5) which has a deletion between nucleotides 2496 and 
3323 in the ElB region encoding the 55kDa protein. In addition, there is a C to 
T transition at position 2022 in ElB which generates a stop codon at the third 
codon position of the protein. These alterations eliminate the expression of the 
55kDa protein in Onyx-015 infected cells. The normal function of this protein 
is to bind to and inactivate the p53 protein in infected cells (Kao et al,1990). 
Because Onyx-015 lacks this protein it should replicate less efficiently in cells 
with functional p53 since it cannot inactivate p53. However it should replicate 
efficiently in cells with non-functional p53 as previously described. Such a 
virus is potentially very important clinically since over 50% of human cancers 
have inactivation of the p53 gene. This virus would allow us to target tumours 
at a molecular level thus limiting any damage to surrounding normal tissue.
1.6. OB.TECTIVES OF PRO.TECT.
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1.6.1. To develop an immunocompetent mouse model to test oncolytic 
adenoviruses(Onyx-015)
At present , there is no immunocompetent mouse model to test 
replicating adenoviruses as it is generally accepted that the infectivity and 
productive replication of adenoviruses in mouse cells is poor. A cotton rat 
model Sigmadon hispidus was described by Pacini et al, 1984 to be permissible 
to human adenovirus and enabled studies to be done on the mechanism of 
action of adenoviral replication in the pathogenesis of pneumonia. A mouse 
model for studying adenoviral pneumonia pathogenesis was later described by 
Ginsberg e t a l ,  1991. In this model it was shown that pneumonia was 
dependent on the expression of early viral genes since replication did not occur 
in the mouse lung. Evidence that replication could occur in mouse tissue but at 
a low level was shown by Eloit et al , 1994 in which he looked at the 
dissemination of wild type, E3 deleted, and E lA  deleted adenoviruses in both 
mice and cotton rats following intranasal inoculation of adenovirus. It was 
found that the dissemination of both the wild type and E3 deleted virus was 
wider than E lA  deleted virus providing evidence that there was a low level of 
replication in the mouse species. Willcox et a l , 1978 also showed that a low 
level of replication was possible in mouse liver. Kelly et al,1978 also showed 
mouse teratocarcinoma cells were permissive to adenoviral infection. However, 
all these studies are not useful for testing oncolytic adenoviruses since the level 
of productive infection is too low in the mouse tissues tested.
We decided to examine a wider range of rodent tissue types for 
adenoviral infectivity and replication. The aim of this was to identify a mouse 
tissue type which could support a productive adenoviral infection and which
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could therefore be exploited for use in immunocompetent mouse models to 
examine the use of oncolytic adenoviruses in cancer therapy.
To develop a mouse model it was necessary to
1. Determine which mouse tissue types were permissible to adenoviral 
infection.
2. Determine whether or not a productive infection could be produced in mouse 
cells.
3. Determine whether or not Onyx-015 had the same p53 selectivity in mouse 
cells as was found in human cells.
4. Determine whether or not Onyx-015 had efficacy in vivo in nude mouse 
p53(-) xenografts.
5. Determine whether or not Onyx-015 had efficacy in vivo in syngeneic mouse 
p53(-) xenografts and to determine the effect of the immune system on efficacy.
1.6.2. To carry out mechanistic studies to explain the mechanism for 
selective replication of Onyx-015 for p53(-) cell lines.
Several publications have disputed the p53 selectivity of the Onyx-015 
virus. Goodrum and Ornelles,1997 showed that replication only occurred in 
cells which were in the S phase of the cell cycle and that this was independent 
of the p53 status of the cell lines studied. Hall et al,1998 recently suggested that 
adenovirus induced cell death was greater in cell lines which had wild type p53. 
Therefore another aim of this thesis was to further examine the mechanism of 
selectivity of Onyx-015 for p53(-) cells. To study this we utilised the human 
ovarian adenocarcinoma cell lines A2780 (functional p53) and A2780Cp70 
(non-functional p53 cisplatin resistant variant ). To do this it was necessary to
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1. Determine whether the infectivities of A2780 and Cp70 to adenoviruses 
were comparable.
2. Determine whether replication of adenovirus was greater in Cp70 compared 
to A2780.
3. Explain mechanistically the differences in replication by cell cycle analysis, 
p53 protein changes, and by examining the mode of cell death i.e. virus 
induced cytolysis or apoptosis.
1.6.3. To determine the effect of Onyx-015 on cytotoxicity induced by DNA 
damaging agents cisplatin and ionising radiation.
The adenoviral E lA  gene is able to induce apoptosis in cells by p53 
dependent and p53 independent mechanisms( Teodoro et al,1995; Debbas and 
White,1993; Lowe and Ruley,1993). The ElB(55kDa) gene can inhibit p53 
dependent apoptosis by binding to the N terminus of p53 causing 
transcriptional repression and promoting p53 degradation via the ubiquitin 
degradation pathway ( Debbas and White,1993; Querido et al,1997; Steeganga 
et al,1997). The ElB(19kDa) gene can inhibit both the p53 dependent and 
independent apoptosis due to its Bcl2 like properties( Han et al,1993; Huang et 
al,1997). Studies have shown that transfecting in the E lA  gene into tumour 
cells which are either wild type or mutant p53 induces apoptosis ( Sanchez- 
Prieto et al,1998). Moreover this apoptosis is enhanced when combined with 
DNA damaging agents (Sanchez-Prieto et al,1996). Rather than transfecting 
E lA  into tumour cells , it would be simpler to infect with an adenovirus which 
retains the E lA  region such as with Onyx-015. Our objective was therefore to 
determine whether or not Onyx-015 could increase cytotoxicity to DNA
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damaging agents in non-functional p53 and also functional p53 cell lines. To 
study this we utilised the human ovarian adenocarcinoma cell lines A2780 
(functional p53) and A2780Cp70 (non-functional p53 cisplatin resistant 
variant).
37
CHAPTER 2 
METHODS AND MA TERIALS
2.1 MATERIALS
2.1.1 Chemicals
All chemicals were of AnalaR grade and were obtained from BDH Chemicals 
Ltd,Poole,Dorset or Sigma Chemicals. Ltd, Poole,Dorset except those obtained 
from the suppliers listed below.
Advanced Biotechnologies Ltd.Surrey 
Taq polymerase 
Advanced Protein Products 
Foetal calf serum
Amersham International PLC.Amersham.Buckinghamshire 
dCTP, dGTP 
rainbow protein markers 
ECL Western blotting detection kit 
Beatson Institute Central Services 
sterile PBS(phosphate buffered saline)
Biogenesis 
RNazol B
Boehringer Mannheim UK Ltd.Lewes.East Sussex
Insitu cell death kit
BRIiUKL Gibco Ltd. Paisley
all restriction enzymes
J.Burrough(FAD) Ltd.Witham.Essex
ethanol
FMC.Rockland.ME
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Nuseive agarose
Gateway plc.Glasgow
Marvel dried non-fat milk powder
Gibco Europe. Life Technologies Ltd. Paisley
Special Liquid Medium(SLM)
10 X  DMEM 
10 X RPMI 
200mM glutamine 
2.5% trypsin 
penicillin 
streptomycin 
RNA ladder 
DNA ladders 
Promega. Madison.WI 
Taq DNA polymerase 
dNTPs
Rathburn Chemicals Ltd. Walkerburn,Peebleshire 
phenol(water saturated)
Severn Biotech, Kidderminster 
acrylamide(30%, 40%) 
bis-acrylamide 2%
Sigma Chemical Co.Ltd.Poole.Dorset
agarose
Tween 20
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ethidium bromide 
TEMED
p- mercaptoethanol 
orange G 
bromophenol blue 
xylene cyanol 
proteinase K 
Rnase 
Pepsin
Propidium iodide
Stratagene. La Jolla. CA
Prime- It RmT Random Primer Labelling Kit
Vector Laboratories Inc, Burlington.USA
Vectashield antifade mounting medium
BCIP/NBT substate
DAB substrate
Nuclear fast red
ABC Mouse peroxidase kit
ABC Rabbit peroxidase kit
2.1.2. Equipment and plasticware
Amersham International PLC.Amersham.Buckinghamshire 
Hybond-N membrane 
Applied Biosvstems Ltd
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PCR reaction tubes( thin walled)
Becton Dickinson Labware. Plymouth. Devon 
tissue culture dishes(90mm,60mm)
Eastman Kodak Co. Rochester. New York 
Ektachrome colour slide film 
Fuji Photo Co.Ltd. Japan 
x-ray film
Gibco Europe, Life Technologies Ltd.Paislev
Nunc 1ml cryotubes
Nunc 8-well chamber slides(permanox)
Nunc 25cm^, 75cm^, 175cm^ tissue culture flasks 
Griener Labortechnik Ltd. Durslev 
eppendorf tubes
Hvbaid Ltd. Teddington. Middlesex 
Omnislide in situ system 
Labsvstems. Basingstoke 
pipette tips
Molecular Bioproducts, San Diego. CA 
aerosol- resistant tips
Pharmacia Ltd. Milton Kevnes.Buckinghamshire 
Nick columns 
Spin columns
Whatman International Ltd. Maidstone 
3MM paper
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2.1.3. Antibodies
Amersham
Bak (mouse monoclonal)
DAKO
Bcl2 (mouse monoclonal) 
mdm2 SMP14(mouse monoclonal)
Oncogene Science
p53 DO-1 (mouse monoclonal)
ElA  M73(mouse monoclonal)
ElB19kDa(rat monoclonal)
Pharmingen
Rb (mouse monoclonal)
Bax(rabbit polyclonal)
Santa Cruz
p21 SC-397 (rabbit polyclonal)
Sigma Chemical Co.Ltd.Poole.Dorset 
vinculin VIN-ll-l(mouse monoclonal)
Fluorescein(FITC) conjugated AffinitiPure Goat Anti-Mouse IgG 
Gifts
RSA3 anti- E4orf6 and E4orf6/7 proteins(mouse monoclonal) - T.Shenk. 
(1990. J. Virology.64:2345-2359).
CM-5 murine p53(rabbit polyclonal) - D Lane (Dept of Biochemistry, 
University of Dundee).
42
mdm2 2A10(mouse monoclonal) - A Levine(Princeton University,USA)
PARP (mouse monoclonal)- K Caldecott
2.1.4. Probes used for Northern blot hybridisation.
a) Preparation ofcçAP3 mouse probe for Northern blotting.
RNA was made from mouse liver using the RNAzol method. cDNA 
was made from RNA using the Perkin Elmar RTPCR kit. Reverse transcription 
was done with Ipig of RNA. The amplification primers for mouse (pAP3 were 
designed using the primer programme Designer PCR using the cDNA sequence 
for mouse (pAP3 published by Fognani and Babiss,1993. The primers used 
were as follows:
5’- AGATGCCAAGGGTACTGTCAT-'3 (forward)
5’- AGGTGTGTCCGGAAGTGTACT-'3 (reverse) 
and this produced a fragment of length 651bp.
Amplification was carried out at 95^C for 3 minutes, then 30 cycles of 
95^C for 30s, 60^C for 30s, 72°C for 30s, followed by a final extension time of 
10 minutes at 72°C. An aliquot was run on a 1% agarose gel(Nu-Sieve) 
containing 0.5p,g/ml ethidium bromide in TBE buffer and then photographed 
under UV light to check for correct amplification. The whole PCR product was 
then run on a 1% agarose gel(low melting point seakem agarose) containing 
0.5pg/ml ethidium bromide in TAE buffer at low voltage of 40V for 2 hours, 
the correct band cut from the gel, and then the PCR product extracted from the 
gel using the Qiagen gel extraction kit(QIAquick gel extraction kit cat#28704).
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b) Preparation o f p21 mouse probe for Northern blotting.
As above. The amplification primers for mouse p21 were designed 
using the primer programme Designer PCR using the cDNA sequence for 
mouse p21 published by Huppi et al,1994.
The primers used were as follows:
5’-TTGTCTCTTCGGTCCCGTGGA -3 (forward) 
5’-TGGTCTGCCTCCGTTTTCGAC -'3 (reverse) 
and this produced a fragment of length 368bp.
2.1.5. Plasmids and restriction digests.
a) Human p21.
The human p21 plasmid used was pCEP-WAF-l(Sense) and was 
donated by Dr Wafik S El-Diery ( El-Diery et al,1992). The 2.1 kb cDNA of 
human p21 was cut out of the plasmid by Notl restriction digest at 37°C in 
React 3 buffer for 90 minutes. The whole restriction product was run on a 1% 
agarose gel (low melting point seakem agarose) containing 0.5pg/ml ethidium 
bromide in TAE buffer at low voltage of 40V for 2 hours, the correct band cut 
from the gel, and then the product extracted from the gel using the Qiagen gel 
extraction kit(QIAquick gel extraction kit cat#28704). This product was then 
further digested with EcoRI at 37^C in React 3 buffer to produce a Ikb product 
which was extracted in the same way. This was used in the Northern blots.
b) Human mdm2.
The human mdm2 plasmid used was pCHDMIA and was donated by Dr 
A Levine (Chen et al,1993). The 1.8kb cDNA of human mdm2 was cut out of
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the plasmid by EcoRI restriction digest at 37°C in React 3 buffer for 90 
minutes. The product was then extracted as described above.
c) Human bax.
The human bax plasmid used was donated by Clare Bradshaw (Beatson 
Research Institute - unpublished data). A 600bp fragment of human bax DNA 
was cut out of the plasmid by a double digest with EcoRI and Notl restriction 
enzymes at 37^C in React 3 buffer for 90 minutes. The product was then 
extracted as described above.
2.2. MOUSE IN VITRO STUDIES.
2.2.1. Cell culture
a) Cell lines.
Mouse epidermal cell lines C5N, CarB, B9, A5, SN161, PI, P6 were 
grown in Special Liquid Medium (GibcoBRL) with 10%FCS and 10%L- 
Glutamine.
C5N...............non-tumourigenic, immortalised keratinocyte cell line
isolated by single cell cloning of MCA3D cells derived from 
Balb/c mouse Kulesz- Martin et al; 1983).
CarB..............highly aggressive spindle cell line isolated from carcinoma
produced in NIH mice following DMBA/TPA treatment. 
(Diaz-Guerra et al; 1992)
P1,P6.............cell lines derived from papillomas induced by treatment of
mus spretus! mus musculus FI hybrid mice with DMBA/TPA 
(Haddow et al; 1991)
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B9..................squamous expiant from the M SCll carcinoma produced by
multiple DMBA treatment of a mus spretuslmus musculus FI 
hybrid mouse (single cell clones) (Burns et al;1991)
A5..................spindle explants from the M SCll carcinoma produced by
multiple DMBA treatment of a mus spretuslmus musculus FI 
hybrid mouse (single cell clones) (Burns et al;1991)
SN161...........squamous/spindle explant derived from a carcinoma produced
by DMBA/TPA treatment of 129/NIH hybrid mouse 
(Haddow et al,1991).
E4................. squamous clone from SN161 cell line.
H l l ...............spindle clone from SN161 cell line.
Mouse melanoma B16F1, mouse kidney adenocarcinoma TCMKl, 
mouse Lewis lung carcinoma, rat thyroid carcinoma VHl VRS2, rat colon 
carcinoma K12/TrB were also grown in Special Liquid Medium (GibcoBRL) 
with 10%FCS and 10%L-Glutamine. Rat glioblastoma 9L-82 was grown in 
Dulbecco’s modified Eagle’s medium (DMEM) with 10%FCS and 10%L- 
Glutamine. Rat Morris hepatoma was grown in 75%DMEM/F12 (1:1), 
5%FBS, 20% horse serum.
b) Long term storage o f  cells
Subconfluent F175 flasks (surface area 175cm^) were trypsinised and 
the cells resuspended in serum containing medium. The cells were then pelleted 
by centrifugation and resuspended in 2.5ml fresh medium and then an equal 
volume of frrezing medium (50% SLM, 30%FCS, 20%DMSO) was added
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dropwise and 1ml aliquots were transferred to -70°C in cell freezing container 
overnight . This permitted slow cooling of the cells to -70°C before the vials 
were transferred to liquid nitrogen for long term storage.
c) Transfection o f  cell lines by electroporation
Transfection was carried out as described by Baum et al,1994. To 
determine the optimum conditions for transfection by electroporation for each 
cell line, transfection was done at a range of voltages and volumes and 
efficiency of transfection determined using a luciferase reporter construct PGL3 
(Promega). Exponentially growing cells were trypsinised and centrifuged to a 
pellet at 1600rpm for 5 minutes. The cells were then resuspended in a volume 
of medium at a concentration of 2 x 10  ^cells/400pil, 2 x 10  ^cells/300pl and 2 
X  10  ^ cells/200fxl. To each of 6 cuvettes was added the 2 x 10  ^ cells in the 
appropriate volume of medium. Ipg of PGL3 luciferase reporter DNA was 
added to each cuvette and then each sample was electroporated at a range of 
voltages from 0.2 to 1.0 Volts. 1ml of medium was added to each cuvette and 
the mixture then added to a 6 well plate with 5ml of medium in each well. The 
cells were incubated at 37^C/5%C02 for 24 hours and the cells harvested 
using a Universal cell scraper into a 20 ml universal container. Cells were 
centrifuged to a pellet at 1600rpm, medium removed , 1ml PBS added and the 
cells transferred to a 1.5ml eppendorf. The cells were centrifuged to a pellet at 
13000rpm for lOseconds, PBS removed and then 50pl of cell lysis buffer 
(Promega) added and the mixture briefly vortexed before incubating on ice for 
10 minutes. Cell debris was pelleted at 13000rpm for 1 minute and then 5pil of 
supernatant transferred to a 0.5ml eppendorf. 50p,l of luciferase assay solution
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(Promega) was added to each eppendorf and the fluorescence measured using a 
scintillation counter. The sample with the maximum fluorescence value 
indicated the optimum conditions of volume and voltage for electroporation.
2.2.2.Vinises
Onyx-015 is a chimeric human group C adenovirus (Ad2 and Ad5) 
which has a deletion between nucleotides 2496 and 3323 in the ElB  region 
encoding the 55kDa protein. In addition, there is a C to T transition at position 
2022 in ElB which generates a stop codon at the third codon position of the 
protein. These alterations eliminate the expression of the 55kDa protein in 
Onyx-015 infected cells (Barker et al,1987).
Ad5CMVlacZ is a nonreplicating E l deleted adenovirus in which the 
reporter construct lacZ has been inserted into the E l region under the control 
of the CMV promoter ( Kolls et a l , 1994).
All adenoviruses were grown on the human embryonic kidney cell line 
HEK293 which expresses the E l region of Ad2 (Graham et a l , 1977) and band 
purified on a CsCl gradient. Stocks were stored at -70°C after addition of 
glycerol to a concentration of 50%vol/vol.
2.2.3. Plaque assays
Plaque assays were performed as described by Graham and Prevec,1991 
to determine the quantity of infectious viral particles in viral stocks and burst 
assays. Briefly, plates were scraped into 0.5ml of media and frozen. Lysates 
were prepared by 3 cycles of freezing and thawing. Serial dilutions on the 
lysates were titred on HEK293 cells.
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2.2.4. Burst assays
Burst assays were used to determine the replication efficiency of Onyx- 
015 and wild type Ad2 in infected cells. Cell monolayers were infected at a 
multiplicity of infection (MCI) of lOpfu/cell with either wtAd2 or Onyx-015. 
After 90 minutes incubation, nonabsorbed virus was washed off with PBS, and 
then medium with 2%FCS added. At 4 hours and 72 hours post infection, cells 
were scraped into 0.5ml of medium and frozen. Lysates were prepared by 3 
cycles of freezing and thawing. Serial dilutions on the lysates were titred on 
HEK293 cells. The burst ratio was expressed as the concentration of virus at 72 
hrs divided by the concentration of virus at 4 hrs post infection.
2.2.5. Infectivity assay- Ad5LacZ assay
Infectivity of cell lines to adenovirus was determined using the 
nonreplicating E l deleted adenovirus with a lacZ reporter construct under 
control of the CMV promoter. Cell monolayers on 60mm plates were grown 
to 70-90% confluence and then infected with Ad5CMVlacZ adenovirus at 10 
pfu/cell and lOOpfu/cell for 90 minutes. Nonabsorbed virus was removed after 
90 minutes and then medium with 2% FCS added. After 24 hours and 48 hours 
incubation, medium was removed, the cells washed once with cold PBS, and 
then fixed with ice cold formaldehyde in PBS for 30 minutes. Monolayers were 
then washed 3 times with PBS , then stained with X-gal solution in the dark for 
24 hours at 37^C. Cells were washed with PBS and then examined using a light 
microscope.The number of blue staining cells to total cells was measured in 5
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separate random high power fields and the mean determined and expressed as a 
percentage.
2.2.6. Cytopathic effect(CPE) assay
Briefly, cells were grown to 70-90% confluence and then infected with 
either Onyx-015 or Ad2 for 90 minutes at MCI of 1 and lOpfu/cell. Plates were 
monitored for CPE and the assay terminated when total cytolysis was observed 
at MCI of 1 pfu/cell with wild type adenovirus.
2.2.7. Immunofluorescence for adenovirus hexon protein
Cells were grown to 70-90% confluence and then infected with either 
Onyx-015 or Ad2 for 90 minutes at MOI of lOpfu/cell. After 72 hours, the cell 
sheet was scraped into the medium and pelleted by centrifugation at 
2000revs/min for 10 minutes.The cell pellet was washed in PBS and then 
resuspended in a small volume of PBS. 25 \i\ aliquots were pipetted onto 6mm 
wells on teflon coated microscope slides (DAKO.Product code No S6114), air 
dried and fixed in acetone at room temperature for 10 minutes.Cells were then 
stained with 25 p.1 of IMAGEN™ adenovirus reagent containing an FITC 
labelled mouse monoclonal antibody to adenovirus hexon protein for 15 
minutes at 37^C in a moist chamber, washed with PBS, air dried, then one drop 
of IMAGEN mounting fluid added and then a cover slip added.The 6mm well 
was then scanned using a confocal fluorescent microscope. Positive hexon 
staining was indicated by bright green fluorescence in the cytoplasm and/or 
nucleus of the cells.
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2.2.8. p53 Functional Assays
a) Radiation induced Gj arrest.
Cells were grown to 10% confluence in SLM medium with 10%FCS on 
90mm culture plates . 5 plates were irradiated at a dosage of 2Gy using a cobalt 
source. 5 other plates acted as controls. Cells were harvested from the 
irradiated and control plates at time points 4, 8, 12, 24 and 48 hours by 
trypsinisation. Cell pellets were obtained by centrifugation at 2,000revs/min 
and discarding the supernatant. The cell pellet was fixed in 70% ethanol on ice 
for at least 1 hour. After washing with PBS, the cells were resuspended in 0.4- 
1.0ml of propidium iodide solution (10 \iglm\ in PBS with Rnase A) for 30 
minutes at room temperature and then examined by flow cytometry.
b) Luciferase reporter assay
This assay was carried out by transfection by electroporation. 
Electroporation conditions were determined for each cell line as described 
before. The constructs used for transfection were tkluc-p53 ( p53 consensus 
binding sequence with luciferase reporter) and the control construct tkluc (no 
p53 consensus binding sequence). These constructs were kindly donated by Dr 
Jinde Zhu. Ipg of each constuct was used for transfection. The luciferase 
control construct PGL3 (Promega) was used to check efficiency of transfection. 
Each experiment was carried out 3 times and the mean value and standard error 
determined for each value.
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2.2.9.Northern Blot analysis.
a) Extraction o f Total RNA from  adherent cells
Total RNA was isolated from actively growing cells by a commercial 
version (Rnazol) of the guanidinium-phenol method (Chomczynski and 
Sacchi;1987). Cells were grown in a 75cm^ flask until subconfluent. The 
medium was aspirated and the cells washed twice in PBS. 3ml of RNazol was 
then added directly to the flask and the lysate was transferred to a 
polypropylene tube. 350^ x1 chloroform was added and after vortexing, the 
lysates were left on ice for 15 minutes, then centrifuged at 10,000rpm for 20 
minutes at 4°C. The upper aqueous phase was then transferred into a new tube, 
and an equal volume of isopropanol was added to precipitate the RNA. The 
mixture was left at 4^C for 3-4 hours. To obtain the RNA , the lysates were 
centrifuged at 10,000rpm for 30 minutes at 4 *^ C, then the pellet was washed in 
75% ethanol, and centrifuged again at 7,000rpm for 20 minutes at 4 ^C. The 
pellet was left to air-dry , dissolved in lOOpl DEPC treated H2O and then stored 
at -20°C.
b) Extraction o f PolyA RNA from  cells.
PolyA mRNA was isolated using the Ambion PolyA RNA isolation 
kit(cat#1915) from the cell lines A5, B9, E4, H ll. 5|xg of RNA was used for 
the detection of qpAP3 on Northern blots.
c) Northern blot transfer o f  RNA
20pig of Total RNA (5pig of Poly A RNA) was fractionated on 1.1% 
agarose gels ( 6% formaldehyde, 0.2M MOPS, 0.5M sodium acetate, O.OIM 
EDTA) in Ix MOPS buffer at lOOV for 4 hours. The RNA was transferred to 
nylon membranes (Hybond N+) using 20x SSC as described by Sambrook et
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al;1989 and fixed by UV crosslinking using a Stratagene UV souce at 1800 
Joules.
d) Radioactive ladelling o f probes by the random priming method
Labelled probes were made by the random priming method. 
Approximately 50-100ng of purified insert DNA was added to a reaction 
mixture ( Stratagene Prime-It RMT cCTP kit) containing oligonucleotide 
labelling buffer and dNTPs. The mixture was then boiled for 5-10 minutes to 
ensure dénaturation, cooled and 1.85mbq of a^^P dCTP and 5 units of Klenow 
enzyme was added. The reaction was incubated at 37^C for Ihr 15mins. The 
unincorporated nucleotides were removed by running the probe through a Nick 
column (Pharmacia) and its activity measured using a scintillation counter. 
The probe was denatured by boiling for 5-10 minutes, and then placed on ice 
for 5 minutes before it was added to the pre-hybridisation buffer.
e) Northern blot hybridisation
Northern blots were prehybridised in Ambion prehyb/hybridisation 
solution(cat#8677) for 3 hours at the temperature of best hybridisation for each 
probe (60^C for qpAP3 , 60^C for p21). ^^ P labelled probe was added and the 
membrane incubated overnight at 60^C. The membrane was washed in low 
stringency wash solution(Ambion cat#8673) x2 at room temp for 10 minutes 
each followed by high stringency wash(Ambion cat#8674) at 42°C x2 for 10 
minutes each before being exposed to X-Ray film. Equal loading of RNA was 
checked by using a GAPDH probe at a hybridisation temperature of 42®C.
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2.2.10. Mouse p53 sequencing
a) RTPCR Analysis.
cDNA was made from RNA using the Perkin Elmar RTPCR kit. 
Reverse transcription was done with lp,g of RNA. The amplification primers 
for mouse p53 were designed from Zakut-Houri et al(1983) and Bientz et 
al(1984). Amplification was performed using amplimers U3 and D5.1. The 
reaction was carried out at 95^C for 3 minutes, then 30 cycles of 95°C for 30s, 
55°C for 30s, 72^C for 30s, followed by a final extension time of 10 minutes at 
72^C. An aliquot was run on a 1% agarose gel(Nu-Sieve) containing 0.5pg/ml 
ethidium bromide in TEE buffer and then photographed under UV light to 
check for correct amplification. Removal of primers and deoxynucleoside 
triphosphates of the PGR products was done using Pharmacia spin columns.
b) Sequencing analysis.
Direct sequencing of the double stranded PGR product was performed 
by a modification of the standard dideoxynucleotide chain terminating method. 
PGR products were directly sequenced with fluorescent dye-labeled 
dideoxynucleotides using Taq polymerase and cycle sequencing. The primers 
used for p53 sequencing were internal primers in the sense direction (U 
amplimers) U8, U6 and UO. The sequencing reactions were performed using 
the Taq DyeDeoxy Terminator Gycle Sequencing kit(ABI, Foster Gity, GA). 
Purified PGR product was amplified at 95°G for 3 minutes, then 25 cycles of 
95^G for 15s, 50^G for Is, 60^G for 4 minutes, followed by cooling to 4°G in a 
Perkin Elmer 9600 PGR machine. The products were then precipitated in 3M 
sodium acetate pH 5.2 and 100% ethanol at -70°G overnight, centrifuged at
15,000 revs/min at 4^G for 15 minutes, washed in 70% ethanol, centrifuged at
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15,000 revs/min, and the cell pellet dried . Electrophoresis was done on a 6% 
denaturing polyacrylamide gel(0.4mm thick), and the bands visualised on the 
Applied Biosystems 373A automatic sequencer.
U8 5'- GCC CCT GTC ATC TTT TGT CCC-3'(264-284)
U6 5'- TGT CCG CGC CAT GGC CAT CTA-3'(459-479)
U3 5’- A CCT CAC TGC ATG GAC GAT CTG- 3’(109-130)
UO 5'- GAG TAT ACC ACC ATC CAC TAC-3'(673-693)
D5.1 5'- CTT GAG GGT GAA ATA CTC TCC-3'(964-984)
2.2.11. Protein Analysis
a) Preparation o f total protein extracts
Subconfluent cells on 90mm diameter culture plates were infected with 
either wild type Ad2 or Onyx-015 at an infectivity of lOOpfu/cell. At different 
times after infection, cells were washed twice in ice cold PBS and then lysed 
with 200 p,L of buffer containing 0.5%NP40, 250mM NaCl, 50mM Hepes 
pH7.0,5mM EDTA,0.5M NaF,200mM Na3V04,100mM benzamidine, lOOmM 
PMSF,10pig/ml each of leupeptin, chymostatin, pepstatin, aprotinin . After 30 
minutes on ice , the lysate was centrifuged at 15,000revs/min at 4 ^C for 20 
minutes to pellet insoluble debris. The protein concentrations of the 
supernatants was determined by the Bio-Rad (Richmond,CA) protein assay. 
h) Immunoblotting
50 pig of protein was suspended in an equal volume of SDS sample 
buffer and separated on an SDS/10% polyacrylamide gel. After 
electrophoresis, the proteins were transferred to an Immobilon membrane
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(Millipore) at a current of 2mA/cm of gel area for 30 minutes using a semidry 
electroblotter. The membranes were then blocked in 5% non-fat milk in 
PBS/0.1% Tween 20 for 3 hours. The membranes were then incubated with the 
primary antibody diluted in blocking solution overnight at 4 and then 
washed with blocking solution x3 for 15 minutes each. The membranes were 
incubated with the appropriate secondary antibody linked to horseradish 
peroxidase ( Santa Cruz) for 1 hour at room temperature diluted in blocking 
solution. After washing in PBS/0.1% Tween20 solution x3 for 15 minutes 
each, the membranes were visualised by enhanced chemiluminescence ECL 
(Amersham, UK). Autoradiograms were scanned and cropped with Adobe 
Photoshop and figures were prepared wih Adobe Freehand software on an 
Apple Macintosh computer.
The following primary antibodies were used:
Protein Antibodv Source Dilution
p53 rabbit polyclonal CM-5 D.Lane 1/2000
p21 rabbit polyclonal sc-397 Santa Cruz 1/500
vinculin mouse monoclonal VIN-11-1 Sigma 1/1000
ElA mouse monoclonal M73 Oncogene Science 1/500
E40RF6 mouse monoclonal RSA3 T Shenk 1/5
E40RF6/7 mouse monoclonal RSA3 T Shenk 1/5
2.3. MOUSE IN VIVO STUDIES
2.3.1. Direct intratumoural injection efficacy studies in Nude mice.
Tumour cells (10^ cells in 200pl of PBS) were injected into the flanks of 
6 week old female athymic nude mice and allowed to grow into palpable
56
tumours (5-8mm maximal diameter). Tumour injection was by a single 
puncture into the centre of the tumour and then directing the needle into four 
quadrants injecting 25% volume into each quadrant. Ad2 treated tumours were 
injected with 10® pfu Ad2 suspended in lOOpil of PBS daily for 5 days. Control 
tumours were injected with vehicle (PBS) in an identical fashion. Onyx-015 
treated tumours were injected with 10® pfu Onyx-015 in the same way. Tumour 
measurements were taken twice weekly by caliper measurement in 2 
dimensions. The volume of each tumour was calculated using the formula 
d^l/2, where d is the smallest diameter in mm and 1 is the largest diameter in 
mm. Tumour volumes were expressed as mm^. The animals were humanely 
killed once tumours were greater than 15mm maximal diameter.
2.3.2. Tumour transplantation into C57bl mice.
PDVc57 tumour cells (10^ cells in 200pl of PBS) were injected into the 
flanks of 6 week old female athymic nude mice and allowed to grow into 1cm 
palpable tumours. Mice were then sacrificed and the tumours dissected out. 
The tumours were cut into 5mm x 5mm x 5mm blocks and then transplanted 
into 4 week old C57bl6 mice. C57bl6 mice were anaesthetised by 
intraperitoneal injection with a 1:1:2 mixture of hypnorm (lOmg/ml), hypnovel 
(5mg/ml) and H2O. Under aseptic conditions , a single cut was made on the 
dorsal aspect of the flank of each mouse and a small subcutaneous pocket 
made. The tumour block was then inserted into the pocket and skin then closed 
with a single metal clip which was removed on day 7. Tumours were allowed 
to establish for 14 days before viral injection studies were done.
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2.3.3. Direct intratumoural injection efficacy studies inC57bl6 mice.
Tumours were established by tumour transplantation from PDVc57 
tumours grown in nude mice. Ad2 treated tumours were injected with 10® pfu 
Ad2 suspended in lOOpil of PBS daily for 5 days. Control tumours were 
injected with vehicle (PBS) in an identical fashion. Onyx-015 treated tumours 
were injected with 10® pfu Onyx-015 in the same way. Tumour measurements 
were taken twice weekly. The animals were humanely killed once tumours 
were greater than 15mm maximal diameter.
2.3.4. Animals and animal care.
Female athymic nu/nu mice were obtained from Harlan Olac at 4-6 
weeks of age. Mice were housed 4 per cage in cages fitted with sterile filter 
tops and fed with sterile food and sterile water. Guidelines for animal care were 
strictly followed.
2.3.5. Analytical and statistical methods.
Mean tumour volumes in treated animals versus controls were 
compared at a given time point using the unpaired two-tailed t-test. Survival of 
animals in each group was analysed using the method of Kaplan and Meier, and 
Kaplan-Meier plots for treated and control groups were compared for statistical 
significance using the Log rank test.
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2.3.6. In situ hybridisation for adenoviral DNA
In situ hybridisation was performed on formalin fixed paraffin 
embedded tumours cut into 5|xm sections. Slides were deparaffinised in xylene, 
hydrated through ethanols 100%, 90%, 70% and then H2O. The tissue was 
digested with proteinase K and post fixed in 4% paraformaldehyde. 
Hybridisation was carried out overnight at 37°C with 0.5pig/ml biotinylated 
adenovirus DNA probe (Enzo Diagnostics,Inc.Farmingdale.NY). After 3 
successive washes in IxSSC at 55°C, an alkaline phosphatase conjugated 
antibiotin antibody (Vector Laboratories) was applied. NBT/BCIP was used as 
the chromagen and slides were counterstained with nuclear fast red (Vector 
Laboratories ).
2.4. HUMAN IN VITRO STUDIES.
2.4.1. Human cell lines
The ovarian adenocarcinoma cell lines A2780 and its cisplatin résistent 
derivative A2780Cp70 were grown in RPMI medium containing 10% FCS and 
10% L-Glutamine. A2780 has wild type p53 sequence and function and 
A2780Cp70 has wild type p53 sequence which is non-functional ( Behrens et 
al, 1987).
All cell lines were grown at 37^C in an incubator adjusted to 5%CÜ2. 
Cells were routinely passaged when subconfluent by aspirating the medium, 
washing once with PBS, and then adding l-2ml of trypsin solution (10%v/v 
trypsin,0.01%EDTA in PBS). Cells were incubated at 37°C until they 
detached ,then resuspended in medium with 10% FCS to inactivate the trypsin, 
then seeded at the appropriate dilution.
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2.4.2. Infectivity assays.
a)AdSLacZ assay.
As described previously.
b) E lA  immunofluorescence assay.
Cell monolayers on 90mm plates were grown to 70-90% confluence 
and then infected with Onyx-015 adenovirus at 10 and 100 pfu/cell for 90 
minutes. Nonabsorbed virus was removed after 90 minutes and then medium 
with 2% FCS added. After 24 hours, cells were harvested by trypsinisation and 
then resuspended in medium. Cytospins were then made using 5 x 10  ^cells per 
slide and ice cold methanol fixation. Slides were washed in PBS and then with 
PBT(PBS plus 0.1% Tween 20) to permeabilise the cells. They were then 
incubated with lOOpl of anti-ElA antibody (mouse monoclonal (Oncogene 
Science) at 1/500 dilution in PBT for 1 hour at 37°C. The cells were washed in 
PBS x2 for 5 minutes each and then incubated with lOOpl of FITC labelled 
anti-mouse IgG (Sigma) at 1/40 dilution at room temperature for 30 minutes. 
Cells were washed in PBS and then counterstained with DAPI solution. The 
slides were then examined by fluorescent microscopy. E lA  positive cells 
stained bright green and negative cells blue with the counterstain DAPI. The 
number of E lA  positive cells was counted in 3 high power fields and the mean 
% of E lA  positive cells calculated.
2.4.3. Replication assays
a) Burst assay.
As described previously.
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b) Hexon protein expression assay.
Cell monolayers were grown to 50% confluence on 90mm plates. One 
plate was infected with Ad2 at lOpfu/cell, one plate with Onyx-015 at 
lOpfu/cell and one plate left uninfected as a control. Nonabsorbed virus was 
removed after 90 minutes and then medium with 2% FCS added. After 48 
hours incubation, the cells were harvested and collected into a cell pellet by 
centrifugation at 2,000revs/min.The cells were fixed in ice cold 70% ethanol 
for at least 1 hour, washed in PBS and then resuspended in 200 microlitres of 
anti-hexon protein antibody(Chemicon #MB805) atl/1000 dilution in PBS for 
1 hour at 37^C. The cells were washed in PBS and then resuspended in 100 pil 
of FITC labelled anti-mouse IgG (Sigma) at 1/40 dilution at room temperature 
for 30 minutes. Cells were washed in PBS and then resuspended in propidium 
iodide solution ( 10 pig/ml) for 30 minutes at room temperature. The cells were 
then analysed by flow cytometry. The percentage of FITC staining cells was 
determined for Ad2 and Onyx-015 infected cells using the control cells as a 
negative control for FITC. Each infection was determined 3 times and the mean 
percentage calculated.
2.4.4. Cell cycle analysis using BrdU and PI.
Cell monolayers were grown to 50% confluence on 90mm plates. Three 
plates were infected with Ad2 at lOOpfu/cell, three plates with Onyx-015 at 
lOOpfu/cell and three plates left uninfected as controls. Nonabsorbed virus was 
removed after 90 minutes and then medium with 10% FCS added. After 0, 24, 
48 hours incubation, BrDU at a concentration of lOpiM in medium was added 
for 1 hour. This was then aspirated, the cells washed with PBS and then
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harvested and collected into a cell pellet by centrifugation at 2,000revs/min.The 
cells were fixed in ice cold 70% ethanol for at least 1 hour, washed in PBS x2 
for 5 minutes each. The cell pellets were then resuspended in 1ml of pepsin 
(1 mg/ml) for 30 minutes , centrifuged at 2000rpm, supernatant removed, and 
the cell pellet resuspended in 1ml of 2M HCL for 30 minutes. After 
centrifugation at 2000rpm for 5 minutes, the acid supernatant was removed and 
the cell pellet washed in PBS and then PBT(PBS with 0.5% BSA and 0.1% 
Tween 20). After centrifugation at 2000rpm for 5 minutes , the cells were 
resuspended in lOOpil of mouse anti-BrdU(DAKO) at 1/30 dilution in PBT for 
1 hour at RT. The cells were washed in PBT x2, then resuspended in 100 pil of 
FITC labelled anti-mouse IgG(Sigma) at 1/40 dilution at room temperature for 
30 minutes.Cells were washed in PBS and then resuspended in propidium 
iodide solution (10 |ig/ml) for 30 minutes at room temperature. The cells were 
then analysed by flow cytometry.
2.4.5. E2F Bandshift assay.
a) Preparation o f  protein extract.
Cell monolayers were grown to 50% confluence on 90mm plates. Three 
plates were infected with Ad2 at lOOpfu/cell, three plates with Onyx-015 at 
lOOpfu/cell and three plates left uninfected as controls. Nonabsorbed virus was 
removed after 90 minutes and then medium with 10% FCS added. After 0, 24, 
72 hours incubation, the cells (floating and adherent) were harvested and 
collected into a cell pellet by centrifugation at 2,000revs/min.The cells were 
then washed in PBS and then lOOp-1 of lysis buffer added. The lysis buffer was 
made fresh and consisted of 20mM HEPES pH7.9, 0.4M NaCl, ImM EDTA,
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20% glycerol, ImM DTT, ImM PMSF, 0.5p.g/ml leupeptin, 0.5p,g/ml 
aprotinin, lp,g/ml chymotrypsin. The cells were incubated on ice for 20 minutes 
, freeze/thawed (dry ice to ice) x2, centrifuged at 14,000rpm for 20 minutes at 
4®C and the supernatant separated into a separate eppendorf. The protein 
concentration was determined by the Coomassie method.
b) Labelling o f  E2F oligonucleotide probe.
The oligonucleotide with the consensus binding sequence for E2F is 
shown below:
GATCTAGTTTTCGCGCTTAAATTTGA
300ng of probe was end- labelled with a^^P labelled dGTP . The 
reaction mixture consisted of 300ng probe, 2p,l lOx React3, 5[xl a^^P dGTP, 
2pil of Klenow enzyme (lunit/p.1), and lOp.1 ddHzO. The mixture was incubated 
at RT for 30 minutes and then excess a^^P dGTP removed using a Qiagen 
nucleotide purification column.
c) Reaction ElFlprobe complex formation.
To lOpig of protein extract was added 5p,l of 4xReaction Buffer, 2pig of 
salmon sperm DNA, 300ng of double stranded competitor oligonucleotide, 
0.5p,l of BSA(10mg/ml) and ddH20 to a final volume of 19pil. After incubation 
at RT for 10 minutes, labelled probe ( equivalent to 150cps on Geiger counter) 
was added and then incubated for a further 20 minutes at RT. The sample was 
then loaded onto a 4.5% polyacrylamide gel for electrophoresis.
4x Reaction buffer consisted of 40mM HEPES pH 7.9, 400mM Kcl, 
4mM EDTA, 16% Ficoll, ImM DTT. The sequence of the competitor
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oligonucleotide for E2F is shown below with nucleotide mutations shown in 
bold:
GATGTAGTTTTCGATATTAAATTTGA
d) Gel electrophoresis.
Samples were loaded onto a 4.5% polyacrylamide /TBE gel 
(Acrylamide/Bis : 29/1). Electrophoresis was carried out in 0.25x TBE running 
buffer at lOOV for 2 hours at 4^C. The gel was then fixed in 10% 
Methanol/10% Acetic acid at RT for 15 minutes with shaking, vacuum dried, 
and then exposed to X-Ray film.
e) Supershift assays.
To identify the E2F complexes, antibodies to E2F1, E2F4, E2F5, DPI 
were added to the reaction mixture to disrupt the complexes. The antibodies 
used were the following:
E2F1 rabbit polyclonal Ed Harlow
E2F5 rabbit polyclonal Nick La Thangue
DPI rabbit polyclonal Nick La Thangue
2.4.6. Apoptosis detection by TUNEL staining.
Cell monolayers of A2780 on 90mm plates were grown to 50% 
confluence and then infected with Ad2 adenovirus or Onyx-015 at 100 pfu/cell 
for 90 minutes. Nonabsorbed virus was removed after 90 minutes and then 
medium with 10% FCS added. After 0, 24 and 72 hours cells (floating and 
adherent) were harvested by trypsinisation and then resuspended in medium. 
Cytospins were then made using 5 x 10  ^cells per slide. Cells were then fixed in
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4% paraformaldehyde at RT for 30 minutes. Slides were washed in PBS and 
then permeabilised with 0.1% Triton X-100, 0.1% Na Citrate for 2 minutes at 
4^C. The slides were then washed in PBS and then 50p,l of TUNEL reagent 
(Boehringer Mannheim in situ cell death detection kit fluorescein) added to the 
slide and incubated for 1 hour at 37°C in an humidified chamber in the dark. 
The cells were washed in PBS x2 for 5 minutes each and then incubated with 
lOOfxl of anti-adenoviral hexon protein mouse monoclonal antibody 
(Chemicon) at 1/1000 dilution for 1 hour at 37®C in an humidified chamber in 
the dark. After washing in PBS, lOOpl of anti-mouse Texas Red was added at a 
dilution of 1/50 and the cells incubated for 1 hour at 37^C in an humidified 
chamber in the dark. Slides were washed in PBS and then counterstained with 
DAPI/antifade solution. The slides were covered with coverslips and sealed 
with nail varnish. The slides were then examined by fluorescent microscopy. 
Apoptotic cells stained bright green, hexon positive expressing cells bright red , 
and uninfected cells blue with DAPI counterstain.
2.4.7. Protein Analysis
a) Preparation o f  total protein extracts - as described previously.
b) Immunoblotting
As described previously with the exception of gel electrophoresis 
for Rb protein. With Rb , electrophoresis was done on SDS/7.5% 
polyacrylamide gels. The polyacrylamide had a low percentage of crosslinker 
bis acrylamide (1:120) to obtain good separation of the different 
phosphorylated forms of Rb.
65
The following primary antibodies were used:
Protein Antibodv Source Dilution
p53 mouse monoclonal DO-1 Oncogene Science 1/1000
p21 rabbit polyclonal sc-397 Santa Cruz 1/500
vinculin mouse monoclonal VIN-11-1 Sigma 1/1000
Rb mouse monoclonal Pharmingen 1/1000
mdm2 mouse monoclonal ElO A Levine 1/100
ElA mouse monoclonal M73 Oncogene Science 1/500
ElB(19kDa) rat monoclonal Oncogene Science 1/500
E40RF6 mouse monoclonal RSA3 T Shenk 1/5
E40RF6/7 mouse monoclonal RSA3 T Shenk 1/5
Bcl2 mouse monoclonal DAKO 1/1000
B cIxl mouse monoclonal Transduction labs 1/1000
Bax rabbit polyclonal Pharmingen 1/1000
Bak mouse monoclonal Amersham 1/1000
PARP mouse monoclonal K Caldecott 1/1000
2.4.8.Northern Blot analysis.
a) Extraction o f Total RNA from adherent cells
Total RNA was isolated by the RNAzol as described previously.
b) Northern blot transfer o f RNA
As described previously.
c) Radioactive ladelling o f probes by the random priming method
As described previously.
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d) Northern blot hybridisation
Northern blots were prehybridised in Ambion prehyb/hybridisation 
solution(cat#8677) for 3 hours at the temperature of best hybridisation for each 
probe (42^C for p21, mdm2, bax.). labelled probe was added and the 
membrane incubated overnight at the hybridisation temperature.The membrane 
was washed in low stringency wash solution(Ambion cat#8673) x2 at room 
temp for 10 minutes each followed by high stringency wash(Ambion 
cat#8674) at 42°C x2 for 10 minutes each before being exposed to X-Ray film. 
Equal loading of RNA was checked by using a GAPDH probe at a 
hybridisation temperature of 42°C.
2.4.9. Clonogenic assay
a) Onyx-015.
Cells were seeded at a density of 5 x 10  ^ per 90mm plate and infected 
with Onyx-015 at an MCI of 1, 10, and lOOpfu/cell with a mock uninfected 
control plate for 90 minutes. Excess virus was then removed and then medium 
with 10% FCS added. After 24 hours, cells were harvested by trypsinisation 
and then plated at a density of 10  ^per plate. 5 plates were used for each MCI. 
10 days of incubation at 37°C was required for colony formation to occur. 
After this period, medium was removed, cells washed with PBS, and then fixed 
with methanol for 30 minutes. After air drying the plates overnight, the 
colonies were stained with crystal violet and then colonies greater than 50 cells 
counted using the colony counter (PROTOS). The mean colony count per MCI 
was calculated and then expressed relative to the uninfected mock control. 
Graphs of percentage survival versus dose of virus (MCI) were then plotted.
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b) Onyx-015 and cisplatin.
After infection with virus as described above, cells were exposed to 
cisplatin at either 24 hours post infection or 72 hours post infection. Cells were 
exposed to cisplatin for 1 hour at doses of 1, 5,10, 20 jxM for A2780 and doses 
20, 40, 60, 80 p,M for A2780Cp70. Cells were then trypsinised and plated out 
as described above.
c) Onyx-015 and radiation.
After infection with virus as described above, cells were exposed to 
ionising radiation from a cobalt source at either 24 hours post infection or 72 
hours post infection. Cells were exposed to radiation doses of 0.25, 0.5,1, 2Gy 
for A2780 and doses 0.5,1, 2, 4Gy for A2780Cp70. Cells were then trypsinised 
and plated out as described above.
2.4.10. Immunoprécipitation
a)Preparation o f  protein lysates.
Subconfluent cells on 90mm diameter culture plates were infected with 
Onyx-015 at an infectivity of lOOpfu/cell. At 8, 24, and 72 hours after 
infection, cells were washed twice in ice cold PBS and then lysed with 150 p,L 
of REPA buffer containing 1% sodium deoxycholate, 0.1% SDS, 1% Triton X- 
100,150mM NaCl, 50mM Tris pH7.4, 200mM Na3V04, lOOmM benzamidine, 
lOOmM PMSF,10pig/ml each of leupeptin, chymostatin, pepstatin, aprotinin . 
After 30 minutes on ice , the lysate was centrifuged at 15,000revs/min at 4 °C 
for 20 minutes to pellet insoluble debris. The protein concentrations of the 
supernatants was determined by the Bio-Rad (Richmond,CA) protein assay.
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b) Immunoprécipitation.
The volume of 200pg of protein was estimated and the final volume 
adjusted to 200[xl with RIPA buffer. To each sample was added lp.g of DOl 
mouse monoclonal p53 antibody and the mixture incubated with agitation at 
4^C overnight. p53 protein complexes were then immunoprecipitated with 
100|il of protein A sepharose (Sigma) at 4°C for 1 hour with gentle agitation. 
After centrifugation at 14,000rpm for 30sec, the supernatant was removed , the 
cell pellet washed twice with 500p,l of RIPA buffer , and then an equal volume 
of SDS loading buffer (50fxl) added to the cell pellet (~50p.l). The mixture was 
boiled for 3-5 minutes, centrifuged briefly at 14,000rpm for 30sec, and the 
supernatant removed and then loaded onto an SDS/10% polyacrylamide gel.
c)Electrophoresis and immunoblotting.
Gel electrophoresis and immunoblotting was carried out as described 
before. Mdm2 was detected using mouse monoclonal 2AID supernatant at a 
dilution of 1/50 , followed by peroxidase conjugated goat antimouse secondary 
antibody and then enhanced chemiluminescence. p53 was detected using DOl 
mouse monoclonal antibody, followed by peroxidase conjugated protein A as 
the secondary antibody (to prevent immunoglobulin heavy chains from 
masking the p53 signal at 55 kDa) and then enhanced chemiluminescence.
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CHAPTER 3 
RESULTS
3.1.IMMUNOCOMPETENT MOUSE MODEL TO TEST ONCOLYTIC 
ADENOVIRUSES.
3.1.1. Infectivity and replication of human adenoviruses in mouse cell 
lines.
a) Infectivity o f rodent cell lines.
A nonreplicating E l deleted adenovirus with a lacZ reporter construct 
(Kolls et al,1994) was used to determine infectivity. The percentage of beta- 
galactosidase positive staining cells at a multiplicity of infection (MOI) of 10 
and 100 pfu/cell for several different rodent cell lines is shown in Table 1. 
Infectivity was very high for specific tissue types notably mouse epidermal 
cells, mouse kidney adenocarcinoma TCMKl, rat glioblastoma 9L-82, rat 
thyroid carcinoma VHl VRS2(Figure 8), rat Morris hepatoma. Infectivity was 
very low in mouse Lewis lung carcinoma and rat colon carcinoma K12/TrB 
despite the known tropism for the respiratory and gastrointestinal tracts in 
humans. The infectivity of mouse 3T3 fibroblasts was very low and this was 
significant as much research on adenoviral replication in mouse tissue has been 
done on this tissue type rather than epithelial tissue (Silverstein et 
al,1996).When compared with the human ovarian cell line A2780Cp ,which 
allows efficient viral replication, the infectivity of many of the rodent cell types 
was surpringly higher.
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Cell line Species Tissue Infectivity
%Beta gal +ve 24hrs
10pfu/cell s.a lOOpfu/cell s.a.
A2780Cp7C Human Ovarian adenocarcinoma 14.8 0.9 40.4 1.6
B16F1 Mouse Melanoma 0.7 0 4.8 0.8
Lewis Mouse Lung carcinoma 0.5 0.2 1.5 0.2
3T3 Mouse Fibroblasts 1 0 8.5 1.3
K12/TrB Rat Colon carcinoma 3.5 0.6 8.3 1.1
T C M K l Mouse Kidney adenocarcinoma 19.5 0.8 36.6 1.6
Morris Rat Liver hepatoma 59.6 4.1 100 0
9L-82 Rat Glioblastoma 36.7 2.4 100 0
V H l VRS2 Rat Thyroid carcinoma 31.3 3.7 46.4 3.2
A5 Mouse Epidermal spindle Ca 22 1.8 63.5 1.9
B9 Mouse Epidermal squamous Ca 26.7 1.9 68 3
SN161 Mouse Epidermal sp/sq Ca 16.3 1.3 57.5 4.7
CarB Mouse Epidermal spindle Ca 23.8 2 49.8 4.3
P6 Mouse Epidermal papilloma 16.9 2.2 44.5 2.8
Table 1. Infectivity o f rodent cell lines
Infectivity was carried out using a nonreplicating adenovirus in which the El 
region was replaced with a lacZ reporter construct. The percentage of beta 
galactosidase positive cells was quantified by counting the number of blue 
staining cells in 5 random high power fields and expressing this as a percentage 
of the total number of cells in the fields. The standard error(s.e.) is shown for 
each infectivity result.
Control Ad5LacZ-24hrs
Morris
100%
9L-82
100%
*
8.5%
i
C5N
63.8%
Figure 8. Infectivity of rodent cell lines.
Infectivity was determ ined using an E l deleted adenovirus with a lacZ reporter gene. 
Beta galactosidase staining was carried out at 24 hours post infection and the number 
of blue staining cells calculated. Figure 8shows exam ples of staining in different cell 
lines at an MOI of lOOpfu/cell.
b) Replication and cytopathic effect o f  rodent cells infected with wild type 
Ad2.
Cytopathic effect assays using wild type adenovirus Ad2 were done at a 
MOI of lOpfu/cell. Table 2 shows that cytolysis occurred in all the mouse 
epidermal cells, and to a lesser extent in thyroid carcinoma VHl VRS2 cell 
lines. Some cytolysis was also present in rat colon carcinoma K12/TrB despite 
the low infectivity in this cell line.The presence of the late phase hexon protein 
was detected by direct immunofluorescence. All cell lines which showed a 
positive CPE were positive by immunofluorescence for hexon protein. It was 
interesting to note that the cell lines 9L-82 and TCMKl which were highly 
infectable with the CMVlacZ virus showed no CPE or positive 
immunofluorescence which indicated that there was a block to replication in 
these cell lines as no late phase proteins were expressed. Figure 9 shows a 
typical example of hexon protein staining and CPE in the epidermal cell line 
B9.
c) Productive adenoviral infection in mouse epidermal cells.
To determine if a productive infection could be produced in mouse 
cells, burst assays were done with wild type Ad2. The burst ratio was expressed 
as the concentration of virus at 72 hrs divided by the concentration of virus at 4 
hrs post infection. Figure 10a shows the results of burst assays in cell lines 
B9, SN161 compared to the human ovarian cell line A2780Cp.The burst ratio 
for A2780Cp is x50 greater than B9, x25 greater than SN161. Figure 10b 
shows that the infectivities of each cell line are similar at lOpfu/cell as
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Cell line Species Tissue CPE Hexon staining
B16F1 Mouse Melanoma - -
Lewis Mouse Lung carcinoma - -
3T3 Mouse Fibroblasts - -
K12/TrB Rat Colon carcinoma + +
TC M K l Mouse Kidney adenocarcinoma - -
Morris Rat Liver hepatoma - -
9L-82 Rat Glioblastoma - -
VHl VRS2 Rat Thyroid carcinoma + +
A5 Mouse Epidermal spindle Ca + +
B9 Mouse Epidermal squamous Ca + +
SN161 Mouse Epidermal sp/sq Ca + +
CarB Mouse Epidermal spindle Ca + +
P6 Mouse Epidermal papilloma + +
C5N Mouse Immortalised keratinocyte + +
Table 2. • Cytopathic effect(CPE), and imniunofluorescence(IF)for hexon protein of wild type 
adenovirus infected rodent cell lines.
Cytopathic effect and immunofluorescence were done at a MOI of lOpfu/cell. For CPE, plus and minus 
symbols refer to the presence or absence of cytolysis. For hexon protein staining, plus and minus symbols 
refer to the presence or absence of green fluorescent hexon protein staining cells.
eFigure 9. Cytopathic effect and hexon protein staining in cell line B9.
Figure 9a and 9b show uninfected cells at 0 hours and 72 hours respectively. Figure 9c shows 
cells undergoing cytolysis at 72hours post infection with Ad2 at lOpfu/cell.Figure 9d shows B9 
cells stained for adenovirus hexon protein at 72 hours post infection. Green staining cells are 
hexon positive cells. Uninfected cells stain red with the counterstain Evans blue.
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determined using the LacZ adenovirus. These results show that mouse 
epidermal cell lines can produce a productive viral yield but that the efficiency 
is x25-50 less than human cells.
d) Early adenoviral gene expression o f infected rodent cells.
Previous results on rodent fibroblasts have suggested that the 
expression of adenovirus E lA  is repressed following viral uptake by the 
presence of a trans-acting transcriptional repressor protein (j)AP3 (Fognani and 
Babiss ,1993). In order to determine whether this mechanism is operative in a 
wide range of rodent cell types, protein lysates were made from cells 24hours 
after infection with Ad2 at a MOI of lOOpfu/cell. Western immunoblotting was 
carried out using the mouse monoclonal antibody M73 which detects the E lA  
proteins. A vinculin mouse monoclonal antibody was used as a loading control. 
Figures 11a and 11b show that all rodent cells were able to express the early 
gene ElA  proteins after infection. E lA  expression was expressed relative to 
vinculin expression for each cell line using densitometry (Table 3) and then 
expressed as a percentage relative to the cell line with maximum E lA  
expression which was Morris liver hepatoma cell line .
Within the limits of this experiment (vinculin levels may also vary 
between different cell lines) there was no obvious correlation between E lA  
expression and infectivity e.g. the Morris hepatoma cell line which is highly 
infectible has the highest E lA  expression, but cell line 9L-82 which is equally 
infectible has only 20% ElA  expression compared to Morris. Similarly, 
TCMKl is relatively highly infectible but has low E lA  expression. Within the
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Figure 11. E lA  expression o f infected rodent cells.
Figure 11a shows E lA  expression in mouse epiderm al cell lines. 
E lA  expression is lower in the spindle cell lines CarB and A5 
com pared the other cell lines which are squamous. Figure 11b 
shows E lA  expression in different cell types.
Cell line Species Tissue R elative E lA  exp"
%
B16F1 Mouse Melanoma 30.8
Lewis Mouse Lung carcinoma 12.3
3T3 Mouse Fibroblasts ND
K12/TrB Rat Colon carcinoma 48.9
TC M K l Mouse Kidney adenocarcinoma 6.3
Morris Rat Liver hepatoma 100
9L-82 Rat Glioblastoma 19.2
VHl VRS2 Rat Thyroid carcinoma 85.2
A5 Mouse Epidermal spindle Ca 11.3
B9 Mouse Epidermal squamous Ca 36.2
SN161 Mouse Epidermal sp/sq Ca 20.8
CarB Mouse Epidermal spindle Ca 14.8
P6 Mouse Epidermal papilloma 56.8
C5N Mouse Immortalised keratinocyte 61.8
Table 3. Relative E lA  expression o f  wild type adenovirus infected rodent cell lines.
ElA expression was expressed relative to vinculin expression for each cell line using 
densitometry and then expressed as a percentage relative to the cell line with maximum 
ElA expression which was Morris liver hepatoma cell line.
epidermal cell lines tested, all of which have comparable infectivities, the E lA  
expression also varied .
There was also no obvious correlation between ElA  expression levels 
in the different tissue types and ability to support replication, e.g. Morris 
hepatoma showed high infectivity, high E lA  expression, but no evidence of 
replication as determined by hexon protein staining. In fact, hexon protein 
expression was only present in the colon cell line K12/TrB and the thyroid cell 
line VHl VRS2 and in both of these cases was much less than squamous 
epidermal cell lines tested. This indicated that there was a block to late phase 
protein expression in most tissue types with the exception of mouse epidermal 
cells. However, when we compared ElA  expression with replication in the 
epidermal cell lines we found a relatively good correlation. We compared E lA  
expression levels in two independent pairs of well differentiated squamous cell 
lines (B9 and E4) with their undifferentiated spindle counterparts (A5 and H ll  
respectively). In each of these pairs of cells the spindle variant was derived 
from the same primary tumour as the squamous cell (Stoler et al,1993; Burns et 
al ,1991). Figure 12 shows that E lA  expression correlated with the degree of 
cellular differentiation, with poorly differentiated cells i.e. spindle cell lines 
showing reduced expression. The more differentiated cells also were more 
permissive for replication, as shown by the relatively increased staining with 
anti-hexon protein antibodies. Preferential replication of Ad2 for well 
differentiated cells has also been reported for human kératinocytes (Laporta and 
Taichman ,1981).
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Figure 12. E lA  expression and hexon protein staining in squam ous/spindle 
paired cell lines.
Figure 12a shows that E lA  expression and hexon protein expression is greater in 
the squam ous phenotype B9. Similarly, in Figure 12b. the squamous cell line E4 
also expresses E lA  and hexon protein to a greater extent than the spindle cell line 
Hl l .
B9 A5 E4 H ll
2.1kb (j)AP3
1.3kb
k m # # GAPDH
Figure 13. niRNA expression of 0AP3 in squam ous/spindle paired 
epiderm al mouse cell lines.
The expression of <I)AP3 is much lower in the spindle phenotype for both 
pairs of cell lines.Tliis suggests that reduced expression of E lA  in the 
spindle cell lines is due to high expression of the (t)AP3 protein.
e) Expression o f  (pAP3 determines E lA  expression in mouse epidermal cell.
We hypothesised that the reduced E lA  expression in the spindle 
epidermal cells may be due to repression of the E lA  promoter by the nuclear 
factor ())AP3 , as described in mouse fibroblasts by Fognani and Babiss ,1993. 
We therefore examined the expression of (j)AP3 mRNA in the paired cell lines 
A5(spindle) vs B9(squamous) and H ll  (spindle) vs E4(squamous). We made a 
651bp probe to detect the (j)AP3 mRNA which was of length 2.1kb using 
GAPDH as a loading control. Figure 13 shows that in both cell pairs (j)AP3 
mRNA expression was 20 fold higher in the spindle cell phenotype (A5 and 
H ll)  compared to the squamous cell phenotype (B9 and E4 respectively) This 
suggested that reduced expression of E lA  and therefore reduced replication in 
the poorly differentiated cell type (i.e. spindle ) was due to high expression of 
the (j)AP3 gene.
3.1.2. Selective replication of an ElB deficient adenovirus in mouse 
epidermal cell lines.
a) p53 sequence and protein expression o f mouse epidermal cell lines.
The p53 sequence of the mouse epidermal tumour cell lines A5, B9, 
PDVc57 and SN161 have all been previously published (Burns et al,1991) and 
are mutant. The p53 sequence spanning the highly conserved domains II-V in 
the cell lines CarB(carcinoma), PI (papilloma) , P6(papilloma) and C5N( 
immortalised keratinocyte) were amplified by polymerase chain reaction (PCR)
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, fragments purified and directly sequenced using internal primers. All 4 cell 
lines were shown to have wild type sequence.Table4
Protein lysates were made from exponentially growing cells and 
Western immunoblotting carried out to detect p53 protein expression using the 
rabbit polyclonal antibody CM5 which is specific for mouse p53. Figure 14 
shows that the 4 cell lines with wild type p53 also have very low protein 
expression, whereas the mutant p53 cell lines A5, B9, PDVc57 express very 
high levels of protein.The cell line SN161, which has an 8 base pair deletion in 
the p53 sequence expressed no detectable p53 protein. Thus the protein 
expression results are consistent with the mutational analysis.
b) p53 functional status by radiation induced G1 arrest.
4 cell lines were analysed for radiation induced G1 arrest- CarB, C5N, 
B9,SN161. Both CarB and C5N which have wild type p53 showed a G1 arrest 
at 10-12 hours post radiation as shown in Figure 15. For C5N the S phase 
fraction decreases from 42.7% to 19.5% and the G1 fraction increases from 
36.1% to 55% from 4 hours to 10 hours post radiation. The S and G1 phase 
fractions in the control samples remain unchanged. For CarB, we also see a 
decrease in the S phase fraction (for both diploid and tetraploid populations) at 
10 hours post radiation and this is associated with an increase in the G1 phase 
fraction. Western immunoblotting for p53 and p21 protein also show induction 
of both p53 and p21 with radiation.(Debbie Stuart- unpublished results) . In 
contrast, the cell lines B9(point mutation in p53) and SN161 (8bp deletion in 
p53) showed no G1 arrest although both showed a very strong G2 arrest as 
shown in Figure 16.
75
n in
in n u U
k u X X
XI O Tf
rr r- n
I
£
§
U
y
efS
co
’C
a
AO
L,
x :30Tf
-o
2
I
Xu(9U
-Q
§
u
2
co
U
ZITi
u
03
c3U
Ic
o
o
CL
3
c3
I
n
a
<n
00
u
o -
a
w
I
K
a
*/i
?
&
o
x:
X
o
CO
73
'5
Î
1
-o
' Ô
o .
'•B
2
I
Cl
-03 -
■$ 
u 
3
1  
C
3 I
73
a
3
O
X
o
f
3
o
<u i2
C 3
f  g-
a.
S «5 -3~ oS
o .
'0
I
a
N
Jl i  A
1 1 1
zc/5
0
1 3■oS
co
trsG\00
Clo
C30
Î
1
o00
oc
oilc
A^A
0\
SQ
g
■oe3
@\CQ
■§
a
3 O
G caa " _
uc
5
•S.
â!
go
oCL
3
a
oo
Z
on
I
oJC
<u
Z
c) p53 functional status by luciferase reporter assay.
Figure 17a shows the results of transfecting a luciferase reporter with 
the p53 consensus binding sequence (p53tkluc) compared to a control without 
the p53 sequence (tkluc). Both CarB and C5N showed increased expression 
compared to controls indicating functional p53 in both of these cell lines. The 
cell lines with mutant p53-B9 and SN161 showed no increase in luciferase 
expression which indicated no functional p53 and this correlated with the 
mutational analysis of these cell lines. As a control to check the p53 
functionality of this reporter construct, wild type p53 was cotransfected with 
the reporter construct in the cell line SN161 which has a deletion in p53 
Figure 17b. As expected luciferase activity increased enormously in the 
presence of wild type p53.
d) Selective replication o f Onyx-015 in p53(-) mouse epidermal cell lines.
Table 5 shows the range of mouse epidermal cells tested. CPE assays 
and hexon protein staining were done on each cell line after infection with wild 
type Ad2 or Onyx-015 at a MOI of lOpfu/cell. Ad2 showed no selectivity and 
was able to replicate in all these cell lines. However, Onyx-015 could only 
replicate in those cell lines with mutant p53 demonstrating the selectivity of 
this virus. Figure 18a shows positive cytolysis after Onyx-015 infection for the 
mutant cell line SN161 compared to cell line P6 which has wild type p53. 
Figure 18b shows positive hexon protein staining in the mutant p53 cell line 
SN161 but no staining in P6.
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Gcp53tk-luc
tk- uc
C5N SN161 
Cell line
a  3.500,000 
g ' 3.000,000 
I  2,500,000 
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SN161 transfec tion
PGL3 Gcp53tk- Gcp53lk- 
luc luc+wtp
Figure 17.
p53 luciferase reporter assays on cell lines CarB,C5N,B9,SN161.
In Figure 17a ,both CarB and C5N show a large increase in luciferase activity after 
transfection with the p53 reporter construct (Gcp53tk-luc). SN161 and 89  show 
sim ilar activities for the vector alone(tk-luc) and p53 construct. In Figure 17b, we 
have cotransfected the p53 reporter construct with wt p53 in SN161 to show that 
the reporter construct functions in the presence of wt p53, PGL3 is a luciferase 
construct used to show the efficiency of transfection control.
Cell line p53 CPE/IF CPE/IF
Onyx-015 Ad2
A5 - + +
B9 - + +
Hll - + +
E4 - + +
SN161 - +
PDVC57 - + +
CarB + - +
P1 + - +
P6 + - +
1° mouse ker + -p +
C5N + + +
Table 5. Cytopathic eMect(CPE) and im m unofluorescence (IF)for hexon  
protein in Ad2 and O nyx-015 infected p53(+) and p53(-) m ouse epiderm al 
cell lines.
CPE and immunofluorescence were carried out at a MOIof lOpfu/cell. Plus or 
minus symbols refer to the presence or absence of cytolysis (for CPE) or green 
fluorescent hexon protein staining cells (for IF).
aControl 72hrs Onyx-015 72hrs
SN161
(mutp53)
P6
(vvtp53)
Figure 18a.
After infection with Onyx-015, the cell line S N 161 (mutant 
p53) shows cytolysis. whereas the cell line P6(wild type p53) 
shows markedly reduced cytolysis.
SN161 - mut p53 » l*6-wt p )3
Figure 18b.
The cell line SN 161 (mutant p53) shows positive hexon protein 
staining after infection with Onyx-015 at MOI of lOpfu/cell. The 
cell line P6( wild type p53) shows no hexon protein staining.
e) Productive adenoviral infection in SN161.
We have previously shown that human adenovirus can produce a 
productive infection in mouse epidermal cell lines. To determine if Onyx-015 
could also produce a productive infection, the cell line SN161 was infected 
with wild type Ad2 or Onyx-015 and serial plaque assays carried out over a 
time course of 72 hours. Figure 19 shows that both viruses produced a 
productive infection and the burst increase were very similar.
J) Replication o f  Onyx-015 in primary mouse kératinocytes.
Although we have shown that Onyx-015 will selectively replicate in 
mouse epidermal cell lines with mutant p53, we also found that primary mouse 
kératinocytes allow replication and lysis. This result would suggest that 
although primary kératinocytes have wild type p53 sequence, the function may 
be repressed. Transgenic mice with a lacZ reporter adjacent to the p53 
consensus binding site have been made recently to examine p53 function in 
mouse tissues in response to DNA damage (Hall et al,1996) In response to 
ionising radiation , mouse kératinocytes in these mice fail to show p53 
transcriptional activity( Debbie Stuart unpublished results). This suggests that 
in primary mouse kératinocytes, the p53 gene is functionally inactive. 
Weinberget al,1995 showed that p53 mediated transcriptional activity increased 
with differentiation in epidermal kératinocytes. Since primary kératinocytes are 
largely derived from the basal layer (undifferentiated) of the epidermis , then 
this may also suggest that p53 transcriptional activity is less active.
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Figurel9.
Serial plaque assay on m ouse epiderm al cell line SN161 infected with Ad2 or 
Onyx-015 at an MOI o f lOpfu/cell.
Both viruses produce a x 1000 fold increase in virus particles over a 48 hour period. 
This shows not only that mouse epiderm al cells can produce an adenoviral burst 
but also that the E lB  deleted adenovirus,O nyx-015, will produce a com parable 
viral yield to the wild type virus Ad2.
g) Replication o f  Onyx-015 is dependent on p21 level in wild type p53 cell 
lines.
The cell line C5N, which we have shown to have p53 wild type 
sequence and function, also allows replication to occur. To further examine the 
mechanism behind this we carried out Western immunoblotting on the cell 
lines with wild type p53 following infection with Onyx-015. Cell lines CarB, 
P6 and C5N were tested. Figure 20 . In all 3 cell lines, there was a large 
induction of p53 protein levels. This effect of ElB deleted adenoviruses in 
human cell lines with wild type p53 has been shown before (Grand et al,1994). 
p53 increases in response to adenoviral infection and remains high due to the 
absence of the ElB gene since the 55kDa protein product is required for p53 
degradation. In all cell lines, the p21 level also rises indicating that p53 remains 
functional. However in the cell line C5N the level of p21 drops rapidly at 
72hours post infection despite high levels of p53, whereas in the cell line CarB 
and P6 the levels of p21 remain high. This may suggest that loss of p21 is 
required for Onyx-015 to replicate in cell lines with wild type p53.
h) Loss o f  p21 is due to post-transcriptional degradation and also 
transcriptional repression.
The loss of p21 may be due to loss of p53 transcriptional activity since 
Onyx-015 still expresses the E40RF6 protein which has been shown by 
Dobner and Shenk, 1996 to inhibit directly the transcriptional activity of p53. 
Alternatively, loss of p21 may be due to post-transcriptional degradation. 
Recently, it has been shown that overexpression of the cellular factor p i20^ "^ ^
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Figure 21. mRNA expressin of p21 in cell line C5N afterinfection with 
Onyx-015 at an MOI of lOOpfu/cell.
p21 niRNA expression is increased at 24 hours post Onyx infection. 
However in figure 20. p21 protein levels are reduced compared to 8 hours 
post infection despite high levels of p53 protein. This indicates that the 
reduction in p21 protein at 24 hours is by post-tianslational degradation. At 
72 hours post Onyx infection, the mRNA p21 levels are reduced compared 
to 24 hours yet figure 20 shows high levels of p53 protein. This would 
suggest that there is also p53 transcriptional repression at 72 hours, possibly 
by the adenovbal protein E40RF6.
leads to stabilisation of p21 protein by a p53 independent post-transcriptional 
mechanism (Fernandes et al,1998). It has also been shown that adenoviral E lA  
can downregulate expression of p i20^ "^  ^ (Fernandes et al,1997) and therefore 
reduce the half-life of p21 protein. To determine whether the loss of p21 was 
transcriptional or post-transcriptional, mRNA levels of p21 in Onyx-015 
infected and mock infected C5N were quantified by Northern blotting. Figure 
21. From this figure we can see that the level of p21 mRNA increases 24 hours 
post infection. However in figure 20, p21 protein levels are reduced compared 
to 8 hours post infection despite high levels of p53 protein. This indicates that 
the reduction in p21 protein at 24 hours is by post-transcriptional degradation. 
At 72 hours post Onyx infection, the mRNA p21 levels are reduced compared 
to 24 hours yet figure 20 shows high levels of p53 protein. This would suggest 
that there is also p53 transcriptional repression at 72 hours, possibly by the 
adenoviral protein E40RF6.(Dobner and Shenk ,1996).
3.1.3. In Vivo Studies.
a) Anti-tumour activity o f Onyx-015 in B9 subcutaneous xenografts in nude 
mice.
The mutant p53 mouse squamous epidermal cell line B9 was selected 
for in vivo testing. Subcutaneous xenografts were formed in nude mice and 
once tumours were 5-10mm in maximum diameter, the tumours were injected 
at lO^pfu with either wild type adenovirus or Onyx-015 daily for 5 days. 
Control tumours were injected with diluent of PBS. Tumour diameters were 
then measured twice weekly and growth curves plotted. Figure 22a shows the 
growth curve for Ad2 and Figure 22b shows the growth curve for Onyx-015.
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Figure 22. Growth curves for B9 nude mouse xenografts injectedwith Ad2 
or Onyx-(U5.
Injection with either Ad2 or Onyx-015 at 10*pfu for 5 daily injections 
produced a reduction in growth compared to control mice. Both curves were 
statistically significant with a p value of 0.005 for Ad2 (very significanOand 
<().(K)1 for Onyx-()15(highly significant).
As can be seen, control tumours continued to grow exponentially whereas Ad2 
and Onyx-015 injected tumours underwent tumour regression. Both curves 
were statistically analysed using unpaired two-tailed t-test and found to be 
statistically significant. The p-value for Ad2 versus Control was 0.005 and the 
p-value for Onyx-015 versus Control was <0.001.
b) Anti-tumour activity o f Onyx-015 in PDVc57 subcutaneous xenografts in 
nude mice.
The mouse cell line PDVc57 has mutant p53 and is a squamous 
epidermal cell line. This cell line grows in the syngeneic host C57bl6 mice and 
therefore is a good model to compare efficacy of virus treatment in both an 
immunoincompetent host (nude mouse) and an immunocompetent host (C57bl 
mouse).
i) Efficacy.
Subcutaneous xenografts were formed in nude mice and once tumours 
were 5-10mm in maximum diameter, the tumours were injected at lO^pfu with 
either wild type adenovirus or Onyx-015 daily for 5 days. Control tumours 
were injected with diluent of PBS. In addition, an extra control arm was 
included to compare the effect of PBS injection with no injection of diluent. 
Tumour diameters were then measured twice weekly and growth curves 
plotted. Figure 23a shows the growth curve for PBS versus no injection. 
Figure 23b shows the growth curve for Ad2 versus PBS and Figure 23c 
shows the growth curve for Onyx-015 versus PBS. As can be seen, PBS control 
tumours continued to grow exponentially and at a slightly faster rate than 
uninjected control tumours (p=0.019). This showed that there was no
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Figure 23. Growth curves for PDVc57 xenografts in 
nude mice injected with Ad2 or Onyx-015(dll520) or 
control solution PBS. Tumour volumes are in mm .^
antitumour effect with the injection procedure alone. Ad2 and Onyx-015 
injected tumours had much slower growth rates compared to PBS control 
tumours. Both curves were statistically analysed using unpaired two-tailed t- 
test and found to be statistically significant. The p-value for Ad2 versus PBS 
was <0.001 and the p-value for Onyx-015 versus PBS was 0.008.
ii)Survival.
Survival of animals in each group was analysed using the method of 
Kaplan and Meier, and Kaplan-Meier plots for treated and control groups were 
compared for statistical significance using the Log rank test. Figure 24a shows 
the survival plot for PBS versus no injection, Figure 24b shows the survival 
plot for Ad2 versus PBS and Figure 24c shows the survival plot for Onyx-015 
versus PBS. As can be seen, the survival plots for PBS versus no injection were 
similar and not statistically significant (p=0.48). The survival plot for Ad2 
versus PBS was significant with a p value of 0.02. The survival plot for Onyx- 
015 versus PBS is shown on Figure 24c. Although the plots show a greater 
survival for Onyx-015 injected tumours, the plots were not statistically 
different (p=0.18).
iii)Viral replication in tumours.
To determine whether or not the anti-tumour effect of Ad2 and Onyx- 
015 was due to viral replication, it was necessary to show the presence of viral 
replication in the injected tumours. Tumours were stained by in situ 
hybridisation using a probe against adenoviral DNA. Figures 25 shows 
examples of typical staining seen. The cells staining positive were always 
located at the border between necrosis and viable tumour. All viral injected 
tumours stained positive by in situ hybridisation. These results showed that the
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Figure 24.
Survival curves for nude mice with PDVc57 xenografts 
injected with Ad2 or Onyx-015.
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Figure25. Detection of adenoviral DNA in FDVC57 nude mouse 
xenografts by in situ hybridisation.
Cells expressing adenoviral DNA slain dark blue and uninfected cells 
stain red with the counterstain nuclear fast red.Figure 25a is at low 
power and figure 25b at high power. Tlie cells expressing adenovirus 
were always located at the area between necrotic tissue and viable 
tumour.
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anti-tumour effect observed in the mouse model was due to viral replication. 
However , if we compare the degree of replication in the PDVc57 mouse 
xenograft with a xenograft derived from a squamous cell cancer cell line from 
humans (BICR16) we can see that the extent of replication is lower (Figure 
26c/d). This is in keeping with our in-vitro results in which we showed that 
replication in the mouse cell line is ~x50 less efficient than the human cell line. 
Also if we compare the growth curves of PDVc57 xenografts with BICR16 
xenografts we can see that in the human xenografts we observe regression of 
the tumours but in the mouse xenografts we only see delayed growth and not 
regression (Figure 26a/b). Therefore in the mouse model, the faster rate of 
growth of the cell line combined with the reduced viral replication of virus in 
the mouse cell line results in delayed growth as opposed to regression of 
tumours.
c) Anti-tumour activity o f Onyx-015 in PDVc57 subcutaneous xenografts in 
syngeneic C57bl6 mice,
i) Ejficacy.
Subcutaneous xenografts were formed in syngeneic mice by tumour 
transplantation and allowed to grow to 5-lOmm in maximum diameter. The 
tumours were then injected at lO^pfu with either wild type adenovirus or Onyx- 
015 daily for 5 days. Control tumours were injected with diluent of PBS. In 
addition an extra control arm was included to compare the effect of PBS 
injection with no injection of diluent. Tumour diameters were then measured 
twice weekly and growth curves plotted. Figure 27a shows the growth curve 
for PBS versus no injection, Figure 27b shows the growth curve for Ad2
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Figure 27. Growth curves for PDVc57 xenografts in 
syngeneic mice injected with Ad2 or Onyx-015(dll520) 
or control solution PBS. Tumour volumes are in mm\
versus PBS and Figure 27c shows the growth curve for Onyx-015 versus PBS. 
As can be seen, PBS control tumours continued to grow exponentially and 
there was no difference to the growth curve of the uninjected group (p=0.68). 
Ad2 and Onyx-015 injected tumours had much slower growth rates compared 
to PBS control tumours. Both curves were statistically analysed using unpaired 
two-tailed t-test and found to be statistically significant. The p-value for Ad2 
versus PBS was 0.012 and the p-value for Onyx-015 versus PBS was 0.013. 
Thus, even though these mice had an intact immune system virus injection was 
still able to reduce the growth of the tumours.
ii)Survival.
Figure 28a shows the survival plot for PBS versus no injection. 
Figure 28b shows the survival plot for Ad2 versus PBS and Figure 28c shows 
the survival plot for Onyx-015 versus PBS. As can be seen, the survival plots 
for PBS versus no injection were similar and not statistically significant 
(p=0.41). The survival plot for Onyx-015 versus PBS was significant with a p 
value of 0.04. The survival plot for Ad2 versus PBS is shown on Figure 28b. 
Although the plots show a greater survival for Ad2 injected tumours, the plots 
were not statistically different (p=0.15).
iii)Viral replication in tumours.
To determine whether or not the anti-tumour effect of Ad2 and Onyx- 
015 was due to viral replication, it was necessary to show the presence of viral 
replication in the injected tumours. Tumours were stained by in situ 
hybridisation using a probe against adenoviral DNA. None of the mice injected 
with Onyx-015 showed any evidence of viral DNA in the tumours. Only 2/6 of 
the Ad2 injected tumours showed viral DNA. This is in comparison to the nude
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Figure 28.
Survival curves for syngeneic mice with PDVc57 xenografts 
injected with Ad2 or Onyx-015.
mouse model where all tumours showed evidence of viral DNA in both Onyx- 
015 and Ad2 injected groups. In addition, the degree of replication seen in the 
syngeneic mouse tumours was also much less than the nude mouse model.
These results suggested that the immune system may be preventing 
efficient replication of virus, either by a rise in neutralising antibody or 
cytotoxic T lymphocyte infiltration. Blood samples from the mice were not 
taken for anti-adenovirus neutralising antibody. However, Smith et al,1996 
have reported a rise in antibody titre in C57bl mice when injected with a 
nonreplicating adenoviral vector. Tumour samples were not stained for CD4 
or CDS lymphocytes since no antibodies are commercially available. The fact 
that we see both an anti tumour effect and survival advantage to virus in the 
syngeneic host could be due to either the effect of immune effector cell 
infiltration, the initial effect of viral replication before virus is eliminated, or a 
combination of these two.
3.1.4. Conclusions
In conclusion, in vitro experiments in mouse cell lines have shown that 
human adenoviruses will infect rodent cell lines with variable infectivity. In 
mouse epidermal cells, a productive viral infection can be produced whereas 
there is a block to replication in other cell types. In mouse epidermal cells, the 
restriction point to replication is at the expression of the early gene ElA. 
Replication is greatest in squamous epidermal cell lines in which there is a high 
expression of ElA. We have shown that there is a correlation between the 
level of E lA  and the nuclear factor cpAPS , a transcriptional repressor of the 
ElA  promoter.
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Using mouse epidermal cell lines of known p53 status and function, the 
selective replication of Onyx-015 for p53(-) cells is in general agreement with 
that reported in human cell lines with a few exceptions. Some cell lines with 
wild type p53 do allow replication of Onyx-015 and this may be related to the 
ability for Onyx-015 to repress p21 levels as shown for the cell line C5N.
Using the , squamous epidermal cell line PDVc57 , in vivo studies have 
shown efficacy in both nude mouse and syngeneic mouse models. However, 
replication is markedly reduced in the syngeneic host suggesting limitation of 
viral replication by the immune system.
3.2. MECHANISTIC STUDIES ON THE SELECTIVE REPLICATION 
OF ONYX-015 IN P53(-) CELL LINES.
Several publications have disputed the p53 selectivity of the Onyx-015 
virus. Goodrum and Ornelles,1997 showed that replication only occurred in 
cells which were in the S phase of the cell cycle and that this was independent 
of the p53 status of the cell lines studies. However although the p53 sequence 
of the cell lines used in this study was known, the functional status was not 
known. Hall et al,1998 recently suggested that adenovirus induced cell death 
was greater in cell lines which had wild type p53. However this paper only 
looked at cell death in the cell lines studies but not the mechanism of cell 
death, i.e. viral replication or apoptosis. Therefore, another aim of this thesis 
was to further examine the mechanism of selectivity of Onyx-015 for p53(-) 
cells. To study this we utilised the human ovarian adenocarcinoma cell lines
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A2780 (functional p53) and A2780Cp70 (non-functional p53 cisplatin 
resistant variant ). To do this it was necessary to
1. Determine whether the infectivities of A2780 and Cp70 to adenoviruses 
were comparable.
2. Determine whether replication of adenovirus was greater in Cp70 compared 
to A2780.
3. Explain mechanistically the differences in replication by cell cycle analysis, 
p53 protein changes, and by examining the mode of cell death i.e. virus 
induced cytolysis or apoptosis.
3.2.1. Infectivity and replication of Onyx-015 in the human ovarian 
adenocarcinoma cell lines A2780 and A2780Cp70.
a) Infectivity o f  A2780 and A2780Cp70 to adenoviruses.
i) Ad5lacZ infectivity assay.
The nonreplicating E l deleted adenovirus with a lacZ reporter construct 
was used to determine infectivity. The percentage of beta-galactosidase positive 
staining cells was determined at MOI of 10 and 100 pfu/cell as described 
before. The percentage of positive staining cells was used as an indicator of 
infectivity. This is shown in Table 6. From this table we can conclude that the 
infectivity was similar for both A2780 and Cp70 at both an MOI of 10 and 
lOOpfu/cell. Examples of positive staining for cell lines Cp70 and A2780 at an 
MOI of lOpfu/cell is shown in Figure 29.
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Figure 29. Beta galactosidase staining in A2780 and C'p70 infected  
with Ad51acZ adenovirus at MOI o f lOpfu/cell.
Cells infected with adenovirus Ad51acZ stain blue. Tlie percentage of 
infected(blue) cells to uninfected (nonblue) cells was calculated and 
was ~12-157f for both cell lines.
A2780 lOplu/ccll A2780 KKhhu/ccll
C p7() lOplu/ccll Cp7() l(K)plu/ccll
Figure 30. E lA  im m unolluorescence o f Onyx-015 infected cells.
Cell lines A2780 and A2780Cp70 were infected with Onyx-015 at an MOI of 10 and 
lOOpfu/cell for 24 hours. Tire percentage of cells infected was determined using 
im m unofluorescent detection of cells expressing the adenoviral E lA  protein. Green 
stained cells are labelled with an FITC labelled mouse m onoclonal antibody to 
adenoviral E lA . Uninfected cells stain blue with the counterstain DAPl. This shows 
similar infectivities for both cell lines at MOI of 10(-8-10%  ) and l(X)pfu/cell(~507r ).
ii) E lA  infectivity assay.
Infectivity was also determined by an ElA  immunofluorescence assay. 
Cells were infected with Onyx-015 at MOI of 10 and lOOpfu/cell and the mean 
percentage of cells expressing E lA  protein at 24 hours determined. The results 
are shown in Table 6 and Figure 30. This showed that similar numbers of cells 
expressed E lA  after infection suggesting equivalent infectivity for A2780 and 
Cp70.
b) Replication o f Onyx-015 in A2780 and A2780Cp70.
i) Burst assay.
To determine if a productive infection could be produced, burst assays 
were carried out with wild type Ad2 and Onyx-015 at an MOI of lOpfu/cell. 
The burst ratio was expressed as the concentration of virus at 72 hrs divided by 
the concentration of virus at 4 hrs post infection. Figure 31a shows the results 
of burst assays. From this we can conclude that a productive infection occurs in 
the cell line Cp70 but not A2780 and this would agree with the p53 selectivity 
of Onyx-015. To further examine this burst assays were also carried on mutant 
p53 transfectants of A2780. We can see from the figure that A2780 transfected 
with the mutant p53 (valine 153) allows a productive infection to occur 
compared to vector alone or A2780.This again confirmed the p53 selectivity of 
Onyx-015.
ii) Hexon protein expression assay.
Replication was also determined by quantifying the percentage of cells 
expressing the late phase hexon protein by FACS analysis. These results were
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Figure 31a/b. Burst assays(a) and hexon protein replication assays(b) 
for A2780, Cp70 , p53 mutant transfectant cell line A2780(mut) and 
vector alone transfectant cell line A2780(v).
obtained by Dr Young Tae Kim and are shown in Figure 31b. These also 
showed that the percentage of hexon positive cells was greater in Cp70 
compared to A2780.
c) Replication in Cp70 is due to an increase in S phase entry.
For replication to occur, adenovirus requires the host cell to be in S 
phase since the adenoviral replication machinery is dependent on the host cell’s 
DNA polymerase for replication. We therefore predicted that the percentage of 
cells in S phase would increase in Cp70 cells infected with Onyx-015 but that 
this would not occur in the cell line A2780 which does not allow replication. 
With wild type Ad2, the percentage of cells in S phase should increase in both 
Cp70 and A2780. To test this hypothesis we infected cells at an MOI of 100 
pfu/cell and then determined the percentage of cells in S phase by pulse BrdU 
labelling. Cells were pulsed with BrdU for 1 hour at time points 0, 24 and 72 
hours post viral infection and the percentage staining positively detected using 
an FITC labelled anti-BrdU antibody by flow cytometry. Figure 32 shows the 
results obtained by 2 repeat experiments. As can be seen , Ad2 induces S phase 
entry in both cell lines (no selectivity) at 24 hours post infection compared to 
uninfected controls in which there is a reduction in S phase cells. Figure 33 
shows an example of BrdU cell cycle analysis in cell line Cp70. With Onyx- 
015 , there is an increase in S phase cells in Cp70 over control but only a very 
small increase in S phase cells in A2780.
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Figure 32. Cell cycle analysis of A2780 and Cp70 infected with Ad2 or Onyx at MOI 
lOOpfu/cell.
Inlccicd cells were harvested at 0 ,24 and 72 hours post infection . S phase cells were 
labelled with BrdU and detected with antiBrdU antibody linked to FITC. G,and G 2 phase 
cells were detected by propidium iodide staining. Quantification o f cells in S,G,and G  ^
phases o f the cell cycle was done by How cytometry and presented as a bar chart as shown 
above. In Cp7(), there is an increase in the % cells in S phase at 24 hours post infection with 
both Ad2 and Onyxinfection. However in A2780, the increase in S phase cells only occurs 
with Ad2 infected cells with only a very slight increase in Onyx infected cells.
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Figure 33. Ceil cycle analysis by BrDlJ labelling of Cp70 infected with A d2 or 
Onyx-015 at MOI of lOOpfu/cell.
The percentage of cells in S phase was determined by BrDU labelling and flow 
cytometry. Cells in S phase tire those in the upper quadrantst upper left quadrant 
represents cells in early S and upper right quadrant represents cells in late S phase.) 
In Cp70. there is an increase in the % cells in S phase for both Ad2 and Onyx-(.)l? 
infected cells.
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Figure34. W estern im munoblot o f Rb phosphorylation in A2780 and Cp70 
after infection with Ad2 or Onyx-015 at MOI of lOOpfu/cell.
There is no significant change in Rb phosphorylation status in either cell line 
indicating that Rb phosphorylation is not required for S phase entry after 
adenoviral infection.
d) S phase entry is not mediated by Kb phosphorylation.
The retinoblastoma protein plays a key role in S phase entry at the Gl/S 
checkpoint (Weinberg,1995 for review). In its active form it exists as a 
hypophosphorylated form bound to E2F. Cyclin dependent kinases 
phosphorylate Rb into the hyperphosphorylated form (inactive) and this causes 
the release of E2F . E2F then activates genes essential for DNA replication 
such as dihydrofolate reductase (DHFR) , DNA polymerase a, thymidine 
kinase, thymidylate synthase by binding to E2F sites in the promoters of these 
genes. This therefore allows S phase entry to occur. We determined the Rb 
phosphorylation status by Western blotting over a time course in both Cp70 
and A2780 infected with Ad2 or Onyx-015. Figure 34 shows the Western 
immunoblots obtained. From these we can conclude that there was no 
significant change in phosphorylation state in either cell line indicating that 
phosphorylation of Rb was not the determinant for S phase entry.
e) S phase entry is mediated by E2F induction.
It is known that the adenoviral E lA  protein can interact directly with 
Rb and cause the release of E2F(Fattaey et al,1993; Ikeda et al,1993). To 
determine whether or not E2F increased after adenoviral infection we utilised 
an E2F band shift assay using the human E2F consensus binding sequence. E2F 
supershift assays were done using antibodies to E2F1, E2F4, E2F5 and DPI to 
determine the E2F subtype which was induced. Figures 35 and 36 show that 
with Ad2 infection there is a very large increase in E2F4 and E2F5 in both 
Cp70 and A2780 at 24 hours which then drops rapidly at 48-72 hours. With 
Onyx-015 infection, we also saw a similar increase in E2F4/5 in both cell
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Figure 35. A2780Cp70 E2F Bandshift assay.
Figure 35a shows the effect of Ad2 and Onyx-015 infection at an MOI of 
lOOpfu/cell on Cp70. In both cases E2F induction occurs at 24 hours post 
infection.The predominant E2F subtype which is induced is E2F4. Figure 35b 
shows a supershift assay using antibodies to E2F5,DP1.E2FI to disrupt the E2F 
complexes. The supershift assay identifies which band represents each E2F 
subtype.
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Figure 36. A2780 E2F Bandshift assay.
Figure 36 shows the effect of Ad2 and Onyx-015 infection at an MOI of 
lOOpfu/cell on A2780. In both cases E2F induction occurs at 24 hours post 
infection.The predominant E2F subtype which is induced is E2E4 and also E2F5
lines. Although the induction of E2F would explain the increase in S phase 
cells with Ad2 infection in both cell lines and also Onyx infection in Cp70, it 
does not explain why E2F induction in A2780 infected with Onyx-015 does not 
cause S phase entry. In fact, the induction in A2780 with Onyx-015 is 
equivalent to that found with Ad2 infection yet Ad2 produces a much larger 
increase in S phase cells. One possible explanation for this could be that high 
levels of E2F in the presence of wild type p53 induces apoptosis as reported by 
Qin et al,1994 and Wu et al,1994. Therefore replication would not occur 
because the cells are forced into apoptosis. We therefore decided to determine 
whether or not there was an increase in apoptosis in A2780 after Onyx-015 
infection and also if p53 increased after Onyx-015 infection.
3.2.2. Onyx-015 induces p53 dependent apoptosis in A2780.
a) Clonogenic survival o f  A2780 infected with Onyx-015.
A2780 cells were infected with Onyx-015 at a MOI of 1,10 and 
lOOpfu/cell for 24 hours , cells harvested and then 10  ^or 10  ^ cells plated out 
and clonogenic survival determined at 10 days. Figure 37 shows the survival 
obtained. As can be seen at lOOpfu/cell only 10-15% cells survive infection.We 
have already shown that viral replication does not occur in A2780 and therefore 
the clonogenic survival curve can not be explained by viral replication. We 
therefore examined for evidence of apoptosis in A2780.
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Figure 37. Clonogenic survival o f A2780 after 24 hours infection with Onyx-015.
Cell monolayers were infected at 1,10 and lOOpfu/cell for 24 hours. 10^ or 10‘* cells 
were then plated out and clones allowed to grow for 10 days. Clones greater than 50 
cells were then counted.
b) Onyx-015 induces apoptosis inA2780.
i) Evidence for apoptosis by cell morphology.
Cells infected with Onyx-015 at an MOI of lOOpfu/cell and then 
harvested by trypsinisation at 0, 24, 72 hours and cytospins made. The cells 
were stained with haematoxylin and then examined for apoptotic bodies. 
Figure 38 shows that at 72hours there is clear evidence for apoptosis with 
cellular fearures of apoptosis appearing in the infected cells compared to 
control uninfected cells.
ii) Evidence for apoptosis by PARP cleavage.
In apoptosis , activation of caspases causes cleavage of many proteins 
including PARP (Poly ADP-ribose polymerase). PARP is cleaved from a 
117kDa protein into an 85kDa and 32kDa protein and this can be detected by 
Western blotting using an anti-PARP antibody. This antibody will detect both 
the 117 and 85kDa proteins. As can be seen from Figure 39 , A2780 infected 
cells showed evidence of PARP cleavage with Onyx-015 and also Ad2 at the 
72 hour time point. This was further evidence of apoptosis occuring in A2780.
Hi) Evidence for apoptosis by TUNEL staining.
Cytospins were also stained for apoptosis using the terminal 
deoxynucleotidyl-transferase-mediated dUTP nick end-labelling (TUNEL) to 
detect cleaved DNA in apoptotic cells. Figure 40 shows Onyx-015 infected 
cells undergoing apoptosis as indicated by the bright green fluorescent bodies. 
Non apoptotic cells stain blue with the counterstain DAPI. Cells which express 
the late phase adenovirus hexon protein are stained red with an antihexon 
antibody linked to Texas Red. As can be seen Ad2 infected cells stain
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Figure 38. Huematoxyllin staining of A2780 cells infected with Onyx-(U5 at MOI lOOpfu/cell
After infection with O nyx-015. ceils undergo apoptosis at 72 hours post infection. Typical densely 
staining slnunken cells undergoing apoptosis are arrowed.
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Figure 39. Western immunoblot of RARP protein cleavage in .\278(1 infected w ith .Ad2 
or Onyx-015.
.After infection with .Ad2 or Onyx-015. F.ARP protein cleavage occurs with a reduction in the 
1 17kDa protein and an increase in the 85kDa protein.
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Figure 40. Apoptosis in A2780 by ÏU N E L  staining.
Alter infection with Onyx-015 at lOOpfu/celL many apoptotic cells are seen at 72 hours. 
These stain green with the FITC labelled TUNEL reagent. Cells were also stained for 
hexon protein expression using an antibody linked to Texas Red. In Onyx-015 infected 
cells very few cells stain for hexon protein indicating no viral replication is occurring. In 
Ad2 infected cells, replication occurs as indicated by tlie many red staining cells. In 
addition apoptotic cells are seen in Ad2 infected cells . Some cells stain for both hexon 
protein and also for apoptosis indicating that before apoptosis occurs a degree of viral 
replication can still occur.
positively for hexon protein but very fe^v Onyx-015 infected cells since 
replication occurs with Ad2 but not Onyx-015. Interestingly, although 
replication occurs in Ad2 infected cells we also see evidence of apoptosis 
occuring.
iv) Apoptosis involves an increase in bax and a reduction in bclxl protein
To determine what proteins might be involved in apoptosis, we looked 
at the Bcl2 family of proteins. These included the survival factors Bcl2 and 
bclxL and the proapoptotic factors bax and bak. Figure 41 shows the results 
obtained. As can be seen levels of bak and Bcl2 remain unchanged. However 
we see a reduction in bclxL and an increase in bax at the 72 hour time point. 
This suggests that these 2 proteins are involved in viral induced apoptosis in 
this cell line.
c) Apoptosis is p53 dependent and is induced by adenoviral E lA  and 
repression o f adenoviral ElB19kDa protein.
i) p53 induction by Onyx-015 is by adenoviral ElA..
Adenoviral E lA  is known to induce p53 (Debbas and White,1993; 
Lowe and Ruley,1993). With wild type adenovirus the large ElB 55kDa 
protein binds to the N terminal end of p53 and represses transcriptional activity 
of p53 (Debbas and White,1993). In addition, E lB  55kDA, along with the 
E40RF6 protein ,complex to p53 mediating the degradation of p53 via the 
ubiquitin degradation pathway (Querido et al,1997; Steeganga et al,1997). Thus 
in cells infected with Ad2 we would expect to see a reduction in p53 protein 
expression. However with adenoviruses deleted in the ElB 55kDA region, no 
p53 degradation would occur (Grand et al, 1994). We therefore wanted to
92
Control Ad2 Onyx-015
------------------- 1---I-----------------1---I-----------------1
) 24 72 24 72 24 72 hrs
Vinculin
Bclx,
Bcl2
Bak
Bax 21
Figure 41. W estern im m unoblotting for the Bcl2 family o f proteins in 
Onyx-015 and Ad2 infected A2780 cells
In both Ad2 and Onyx-015 infected cells there is a reduction in BcIxl and 
an increase in Bax protein at 72 hours post infection. Tlius apoptosis is 
being mediated by these 2 proteins.
examine p53 expression in cells infected with Onyx-015 and also Ad2. Figure 
42 shows Western blotting for ElA, ElB19kDa, p53. As can be seen, with Ad2 
infected cells p53 is initially induced and then drops rapidly to undetectable 
levels by 72 hours. With Onyx-015 infected cells however we see an increase 
in p53 protein expression which continues to high levels at 72 hours. Figure 43 
shows p53 staining of A2780 cytospin preparations infected with Onyx-015. 
This shows very clear accumulation of nuclear p53 over 72 hours.
ii) Apoptosis is not inhibited by adenoviral ElB19kDa.
Interestingly the antiapoptotic protein ElB19kDa is expressed very 
weakly in A2780 (compared to Cp70- see figure 48) and is therefore not able to 
inhibit apoptosis. The expression of ElB19kDa is however higher in the Ad2 
infected cells. This could prevent apoptosis occuring and allow replication to 
occur in Ad2 infected cells. This could explain why replication is seen with 
Ad2 infected cells but not Onyx-015 infected cells. We do not know why there 
is this difference in E lB  19kDa levels . One possibility could be that 
ElB19kDa is repressed by p53 and since p53 is degraded in Ad2 infected cells 
and not Onyx-015 infected cells repression of ElB19kDa would cease to occur 
at 24-72hours post infection. If this indeed was the case we expect to see high 
levels of ElB19kDa in cells which had non-functional p53 such as in Cp70. 
This is indeed what we do see (Figure 48).
Hi) E40RF6 does not repress p53 transcriptional activity
Dobner and Shenk ,1996 reported that E40RF6 is able to repress p53 
transcriptional activity alone. Western blotting for E40RF6, bax , p21 was 
carried out to examine this (Figure 44) . We initially see an induction of p21 
but this drops rapidly at 72 hours and this might suggest that either
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Figure 42. W estern im m unobiot o f E lA , p53 and E lB 19kI)a  protein  
expression in A2780 after infection with A d2 or Onyx-()15.
After infection with either Ad2 or Onyx-015. E l  A is expressed and this 
causes an induction in p53 as shown. In Ad2 infected cells, the level of p53 
drops at 72 hours due to degradation by the E lB 55kD a protein. .After 
infection with the E lB 55kD a deleted adenovirus Onyx-015. the p53 level 
remains high. The antiapoptotic protein E1B19K is very weakly expressed 
and therefore unable to inhibit p53 mediated apoptosis. Tire level of E1B19K 
is higher in the .Ad2 infected cells which could suggest that it may be 
controlled by the expression of p53 in the cells.
ni
X
c
N #
*
C
©
%
ÜL A l
nIf,
c
i î î
zc
5;
<
u.c
*
f. ■—
>< — • —«
?= ;:i if.
I I !
Control
I-------------------1-I------------- r I—   r
0 24 72 24 72 24 72 hrs
Ad2 Onyx-(U5
1 r
Vinculin
p53
p21
Bu\ 21
E40RF6
Figure 44. W estern immunohlots for p53,p21,bax and F40R F6 in A278d 
infected with Ad2 or Onyx-015.
.After infection with .Ad2. p53 degradation occurs by 72 hours. This is associated 
with a reduction in p21 protein levels but an increase in bax. After infection with 
Onyx-015. p53 stabilisation occurs. However we still see a reduction in p21 levels 
suggesting either transcriptional repression of p53 by E 40R F6 or protein 
degradation o f p21. Bax protein levels are increased at 72 hours. Northern blotting 
was carried out to determine whether loss of p21 transcriptional or post 
translational.
transcription of p53 is being repressed or post-transcriptional degradation of 
p21 occurs as is seen in the cell line C5N. However, with bax we see an 
increase in levels at 72 hours. We therefore carried out Northern blots to 
examine the mRNA levels of p21,mdm2, bax post infection Figure 45a. As 
can be seen , p21,mdm2 and bax RNA levels do not decrease at 72 hours . This 
indicates that transcriptional repression of p53 by E40RF6 does not occur in 
this cell line. We did observe this however in the mouse cell line C5N. The 
loss of p21 protein expression in A2780 is therefore post transcriptional . This 
may be due to caspase degradation p21 in the process of apoptosis as reported 
by Levkau et al,1998.
iv) mdm2 mediated degradation o f p53 is inhibited post Onyx-015 infection.
Figure 42 shows that p53 protein levels increase markedly post Onyx 
infection . Northern analysis as shown above would suggest that p53 remains 
transcriptionally active. This would suggest that mdm2 mediated degradation 
of p53 is inhibited, possibly by inhibition of mdm2/p53 complex formation. To 
examine this, p53 complexes were immunoprecipitated with DOl antibody 
and then mdm2 detected with 2A10 mouse monoclonal antibody (Figure 45b). 
From this figure, mdm2 levels initially increase in parallel with the p53 protein 
levels. However, at 72 hours post infection the level of mdm2 drops markedly 
while that of p53 increases indicating that complex formation at 72 hours post 
viral infection is inhibited, de Stanchina ,1998 recently reported that adenoviral 
E lA  induces p53 by induction of p l9  . p l9  has been reported to inhibit mdm2 
mediated degradation of p53 by Zhang et al,1998 and Pomerantz et al,1998 . 
We can therefore conclude that Onyx-015 may mediate p53 induction by the 
same mechanism.
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Figure 45a. i i iR N A  expression o f p21 .iudm 2 and bax in A2780 infected with Ad2 and O n y x -(tl5  
at .M O l of KMipfWcell.
GAPDH IS used as a control for loading. All lanes are etjually loaded except tor lane 5. There is no 
evidence for a reduction in mRNA levels in p21.mdni2 or bax at 72 hours x^>st Onyx-015 infection.
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Figure 45b. p53 and in d iii2  prote in  expression on im m unopréc ip ita tion  o f p53 in cell line .X2780 
infected w ith O n yx-015  at M O I o f KMipfu/cell.
p53 was immunoprecipitated using the mouse monoclonal antibody DU-1. Mdm2 protein complexed to 
p5? was determined using the mouse monoclonal antibody 2A10 . p53 protein levels were determined 
using the same antibody used for immunoprécipitation and using proteinA-hrp as the secondare 
antibody. From this figure, after viral infection p53 levels increase over 72 hours as expected. mdm2 
levels also increase for the first 24 hours indicating transcriptional activation by p53. However the level 
drops rapidly at 72 hours. This may be due to E lA  induction of p l9  . which prevents mdm2 interacting 
with p53.
3.2.3. Onyx-015 kills A2780Cp70 by cytolysis and not by apoptosis.
a) Onyx-015 does not induce PARP cleavage.
We have already shown that Onyx-015 can replicate efficiently in the 
cell line Cp70. Apoptosis does not occur in this cell line as shown by a lack of 
PARP cleavage after infection ( Figure 46).
b) Effect o f Onyx-015 on Bcl2 family o f proteins.
Further evidence for no apoptosis is shown in Figure 47 which shows 
Western blots for the Bcl2 group of proteins. As can be seen, there is no change 
in any of the survival or apoptotic factors. We do see an increase in bak 
expression in both Ad2 and Onyx-015 infected cells but this is not significantly 
different from the increase seen in the control samples at the same time points.
c) High expression o f E lB  19kDa inhibits apoptosis.
Figure 48 shows the expression of the adenoviral ElB19kDa protein . 
In Cp70 this protein is expressed to much higher levels than A2780 and this 
would inhibit apoptosis. This also suggests that ElB19kDa protein may be 
repressed by p53.
3.2.4. Conclusions
In conclusion, we have shown that selective replication for Onyx-015 
occurs in the cell line A2780Cp70 (non-functional p53) compared to the 
parental cell line A2780 (functional p53). Replication is dependent on S phase 
entry of the host infected cell and this is mediated by E2F induction by
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Figure 46. W estern im m unobiot for PARP protein cleavage in 
A 2780Cp70.
A2780Cp70 shows no evidence of apoptosis as indicated by lack of PARP 
cleavage on infection with either Ad2 or Onyx-015. Only the uncleaved 
117kDa protein is detected on Western blotting.
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Figure 47. W estern im m unoblots for Bclx, Bcl2, Bak in 
A2780Cp70.
Cp70 has very high levels of the survival factors Bclx, and Bcl2 which 
do not decrease on infection with either Ad2 or Onyx-015. Although the 
apoptotic factor Bak increases on infection, the level is not significantly 
different from the uninfected protein level. In addition, the apoptotic 
protein Bax is not detectable in uninfected or infected cells.Tlierefore 
overall no is no evidence for apoptosis in Cp70.
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adenoviral ElA. In cell line A2780, E2F induction occurs but S phase entry is 
limited by p53 mediated apoptosis. Thus Onyx-015 cannot produce a 
productive viral yield in A2780 due to apoptosis of the host cell. It is likely that 
the p53 induction seen is due to inhibition of mdm2 mediated p53 degradation 
due to the induction of p l9  by adenoviral ElA. In contrast, A2780Cp70 does 
not undergo apoptosis in response to virus infection and this allows Onyx-015 
to produce a viral yield. The lack of apoptosis seen in Cp70 is due to absence of 
functional p53. High expression of the anti-apoptotic factor ElB19kDa also 
prevents apoptosis in Cp70.
3.3. COMBINATIONAL THERAPY OF ONYX-015 WITH DNA 
DAMAGING AGENTS CISPLATIN AND RADIATION.
Studies have shown that transfecting in the E lA  gene into tumour cells 
which are either wild type or mutant p53, induces apoptosis ( Sanchez-Prieto et 
al,1998). Moreover this apoptosis is enhanced when combined with DNA 
damaging agents (Sanchez-Prieto et al,1996). Rather than transfecting E lA  into 
tumour cells , it would be simpler to infect with an adenovirus which retains 
the E lA  region such as with Onyx-015. Our objective was therefore to 
determine whether or not Onyx-015 could increase cytotoxicity to DNA 
damaging agents in non-functional p53 and also functional p53 cell lines. To 
study this we utilised the human ovarian adenocarcinoma cell lines A2780 
(functional p53) and A2780Cp70 (non-functional p53 cisplatin resistant 
variant).
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3.3.1. Effect of Onyx-015 on cytotoxicity induced by cisplatin and
radiation in A2780.
a) Infection with Onyx-015 fo r  24 hours followed by cisplatin is antagonistic.
Cytotoxicity to Onyx-015 and to DNA damaging agents was determined 
by clonogenic assay. Cell monolayers were initially infected with ONYX-015 
at MOI of 10 or lOOpfu/cell followed by exposure to cisplatin at a range of 
concentations for 1 hour. Cells were then plated out for clonogenic assay. As 
can be seen from Figure 49, infection for 24 hours followed by cisplatin 
produces a survival curve which suggests antagonism since the actual curve 
obtained at lOpfu/cell shows a better clonogenic survival than the predicted 
survival (dotted curves). This could be explained in terms of p53 functionality. 
We have already shown that p21 is induced at 24 hours post infection and this 
may reduce the number of cells in S phase at this time point. Since cisplatin is 
an S phase specific drug it would be less effective at this time point and there 
would be an antagonistic interaction between virus and cisplatin.
b) Infection with Onyx-015 fo r  72 hours followed by cisplatin is additive.
After exposure to virus for 72 hours followed by cisplatin the survival 
curves show additive cytotoxicity as shown in Figure 49. p21 is no longer 
detectable at 72 hours and therefore we may expect more cells to be in S phase 
which would allow cisplatin to form adducts and induce cytotoxicity. Thus the 
antagonistic interaction observed at 24 hours would not be present at 72 hours.
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Figure 49. C lonogenic survival o f A2780 after infection with Onyx-015 followed by 
cisplatin exposure.
Cells were infected with Onyx-015 at MOI of 10 and lOOpfu/cell for either 24 hours 
(Figure 49a) or 72 hours (Figure 49b) and then exposed to cisplatin at 1, 5, 10 and 20 
microM for 1 hour. The clonogenic survival plot for 24 hour exposure to Onyx-015 
shows that the observed survival at MOI 1 Opfu/cell was greater than the predicted 
survivaKcalculated by multiplying the values for cisplatin alone by values for virus 
alone). This suggested an antagonistic interaction between Onyx infection and cisplatin. 
The clonogenic survival plot for 72 hour exposure to Onyx-015 shows observed survival 
equivalent to the predicted.This suggested an additive effect.
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Figure 50. C lonogenic survival o f A2780 after infection with Onyx-015 followed by 
radiation exposure.
Cells were infected with Onyx-015 at MOI of 10 and lOOpfii/cell for either 24 hours 
(Figure 50a) or 72 hours (Figure50h) and then exposed to ionising radiation at 0.25 ,0.5 , 
land 2Gy. The clonogenic survival plot for 24 hour and 72 hour exposure to Onyx-015 
shows that the observed survival at both M O Fs is equivalent to the predicted.This
suggested an additive effect.
cj Infection with Onyx-015 for 24 hours followed by radiation is additive.
After exposure to Onyx-015 for 24 hours followed by radiation Figure 
50 the survival curve for 1 Opfu/cell MOI shows additive cytotoxicity. 
Antagonism is not seen as with cisplatin possibly because radiation is not S 
phase specific in its mechanism of cell kill but will induce DNA strand breaks 
at any phase of the cell cycle. Since radiation and also Onyx-015 can both 
induce a p53 dependent apoptosis , both treatments combined would produce 
enhanced toxicity.
d) Infection with Onyx-015 fo r  72 hours followed by radiation is additive.
After exposure to Onyx-015 for 72 hours followed by radiation Figure 
50 the survival curves show additive cytotoxicity.
These results with either cisplatin or radiation suggest that combination 
therapy with Onyx-015 and DNA damaging agents enhances cytotoxicity in 
cells with p53. This would suggest that if both agents are given systemically, 
there may be an increase in toxicity in normal ( functional p53) tissue and 
clinically this would be undesirable. In local delivery of virus, as with 
intratumoural therapy, this is less of a problem. In this case, Onyx-015 would 
replicate in tumours with mutant p53 and replication would then stop on 
reaching the normal surrounding tissue. This is because the normal (non 
tumour) cells would undergo apoptosis preventing further spread of virus into 
normal tissue. This normal tissue toxicity may be increased if virus is combined 
with DNA damaging agents but this would not be as serious as systemic 
toxicity.
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With heterogeneous tumours which have both wild type and mutant p53 
cells, Onyx-015 would kill mutant p53 cells by replication and wild type p53 
cells by apoptosis. Combining therapy with DNA damaging agents would 
enhance this effect.
Radiotherapy is frequently used to treat primary HNSCC which have a 
lower incidence of p53 mutations. The mechanism of cell death is largely p53 
dependent apoptosis. Theoretically it is possible that a preinjection of tumour 
with Onyx-015 24 hours before radiotherapy may sensitise these tumours to 
radiation.
3.3.2. Effect of Onyx-015 on cytotoxicity induced by cisplatin and 
radiation inCp70.
a) Infection with Onyx-015 fo r  24 hours or 72 hours followed by cisplatin is 
synergistic.
Figure 51 shows the survival curves for combination with cisplatin. 
Exposure to Onyx-015 for either 24 hours or 72 hours followed by cisplatin is 
synergistic in both cases. The cytotoxicity is greatest after 72 hours since 
adenovirus has had greater time to replicate and cause cytolysis.
b) Infection with Onyx-015 fo r  24 hours or 72 hours followed by radiation is 
synergistic.
Figure 52 shows the survival curves for combination with radiation. 
Exposure to Onyx-015 for either 24 hours or 72hours followed by radiation is 
synergistic in both cases. The cytotoxicity is again greatest after 72 hours since 
adenovirus has had greater time to replicate and cause cytolysis.
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Figure 51. C lonogenic survival o f A2780Cp70 after infection with Onyx-015  
followed by cisplatin exposure.
Cells were infected with Onyx-015 at MOI of 10 and lOOpfu/cell for either 24 hours 
(Figure51a) or 72 hours (Figure51b) and then exposed to cisplatin at 20, 40, 60 and 80 
microM for 1 hour. The clonogenic survival plots show that the observed survival at each 
MOI was less than the predicted survivaKcalculated by multiplying the values for 
cisplatin alone by values for virus alone). This suggested a synergistic interaction 
between Onyx infection and cisplatin.
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Figure 52. Clonogenic survival o f A 2780Cp70 after infection with Onyx-015  
followed by radiation exposure.
Cells were infected with Onyx-015 at MOI of 10 and lOOpfu/cell for either 24 hours 
(Figure 52a) or 72 hours (Figure 52b) and then exposed to ionising radiation at 0.5, 1, 2, 
4Gy. The clonogenic survival plots show that the observed survival at each MOI was less 
than the predicted survivaKcalculated by multiplying the values for radiation alone by 
values for virus alone). This suggested a synergistic interaction between Onyx infection 
and radiation.
CHAPTER 4 
DISCUSSION
4.1. IMMUNOCOMPETENT MOUSE MODEL TO TEST ONCOLYTIC 
ADENOVIRUSES.
4.1.1. Infectivity and replication of human adenoviruses in mouse cell 
lines.
Replication of human adenoviruses in mouse cells is thought to be 
severely limited due to low infectivity, repression of the transcription of ElA, 
or lack of synthesis of late structural proteins. We have shown in this report 
that the infectivity of rodent cells is extremely variable, ranging from less than 
1% to about 60% after infection with 1 Opfu/cell. Highly infectible cell lines 
included several which were derived from mouse epidermis, and individual 
lines from mouse glioblastoma 9L-82, mouse kidney adenocarcinoma, rat 
thyroid carcinoma, and rat Morris hepatoma. Poor infectivity was seen in 3T3 
fibroblasts, colon carcinoma, lung carcinoma and melanoma cells.
In tissues which were highly infectible, replication as determined by 
CPE assays and hexon protein staining was highest in mouse epidermal cells 
which have not to our knowledge been studied before for adenoviral infection. 
Using burst assays we have shown that productive infections occur in these cell 
lines, although the process is less efficient than in the control human cells 
tested (ovarian carcinoma A2780Cp70 cells). Replication in all other tissue 
types tested was undetectable, with the exception of the colon cell line 
K12/TrB and the rat thyroid cell line VHl VRS, both of which showed poor 
replication in comparison to the epidermal cell lines. In agreement with the 
work of others ( Silverstein et al, 1986), we have shown that 3T3 fibroblasts are 
poorly infectible, and do not allow virus replication. This has been attributed to
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repression of E lA  synthesis (Babiss et al,1993) and a failure to synthesise late 
structural proteins due to the instability of newly synthesised viral DNA 
(Eggerding et al, 1986) .
Although all of the cells tested showed expression of the adenovirus 
early gene product ElA, there was no overall correlation with the level of 
infectivity or ability to support replication of the virus. Thus, although E lA  is 
clearly essential for replication, it is not in itself sufficient, and the host cell can 
block replication at a level downstream from ElA  expression. The cellular 
factor(s) responsible for this block appear to be absent from epidermal cells, 
which was the only cell t>'pe tested which gave rise to a burst of infectious 
virus. The mouse epidermal cell lines tested were of comparable infectivity, but 
varied in the expression of E lA  and hexon protein. E lA  expression correlated 
with replication (as assessed by late protein expression ) such that cells which 
had high E lA  expression also expressed high hexon protein. The most striking 
observation was that squamous epidermal cells (well differentiated) gave high 
E lA  expression and replication, while clonally related spindle epidermal cells 
(poorly differentiated) derived from the same tumours showed low expression 
of E lA  and hexon protein. This suggested that the expression of early and late 
adenoviral genes was dependent on the state of differentiation of the cell. 
Laporta et al, 1981 have reported that in human kératinocytes , Ad2 
replication, as is also the case for human papilloma viruses, is most efficient in 
the suprabasal cells (differentiated) compared to the basal cells 
(nondifferentiated). Our results on squamous and spindle carcinoma cells 
would also indicate that replication is better in the more differentiated cell 
phenotype, although the mechanistic basis for these observations is unclear.
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Aneskievich et al (1990 ) reported that the block to replication in the human 
basal cells was not in early gene expression but was rather in late adenoviral 
gene expression. In contrast, our results show that the level of E lA  correlates 
quite positively with the extent of replication and late protein expression, but 
negatively with the degree of cell differentiation. One possible explanation for 
this may be that during the transition from a squamous to a spindle phenotype, 
the epidermal cells assume a more fibroblastic character, generally switching 
off expression of the epidermal keratins and E-cadherin, and switching on 
fibroblast markers such as vimentin (Stoler et al,1993). Previous work from 
others (Fognani and Babiss ,1993) has shown that fibroblasts produce a trans­
acting transcriptional repressor which suppresses the activity of the E lA  
promoter. Such a factor, if produced at elevated levels after the squamous- 
spindle transition, could account for the observed decrease in replication 
capacity of the spindle cells.
To examine this hypothesis in more detail, we analysed the expression 
of the nuclear factor (j)AP3 , which has been shown to repress the E lA  promoter 
in mouse fibroblasts as described by Fognani and Babiss, 1993. By testing 
related pairs of cells of different phenotype (i.e. squamous vs spindle from the 
same tumour) we have shown that the expression of (j)AP3 is approximately 20 
fold higher in the spindle phenotype . We can conclude that in mouse 
epidermal cells, the restriction to replication is at the level of early gene 
expression and that this is probably determined by the cellular factor (j)AP3.
In conclusion, we have shown that a series of restriction points exist 
which control the ability of human adenoviruses to replicate in rodent cells. 
Similar restrictions probably exist also in human cells, which show wide
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variations in their ability to be infected by and support replication bf adenovirus 
(Steegenga et al, submitted). Our observations are therefore unlikely to be 
restricted to rodent cells, although further investigations in this area are 
necessary. The restriction points we have seen are at the level of virus entry, 
expression of the early gene product ElA, and subsequent initiation of viral 
replication and late protein synthesis. These studies demonstrated that most or 
all of these restrictions are surprisingly absent in mouse epidermal cells, which 
showed the highest ability to support productive replication, leading to a burst 
of infectious virus. Replication is most robust in well differentiated epidermal 
tumour cells ( squamous phenotype) compared to poorly differentiated cells 
(spindle phenotype), probably due to the relative levels of E lA  and its 
transcriptional repressor (j)AP3 . These observations are not attributable to 
more relaxed control of DNA replication in epidermal tumours, since 
additional studies using primary epidermal kératinocytes have demonstrated a 
similar level of replication and hexon protein staining to that seen in the tumour 
lines (data not shown).
These studies therefore establish the basis for the further development 
of epidermal tumour models for testing replication competent adenoviral 
therapy for cancer. Using mouse squamous epidermal tumour cell lines, or 
primary tumours induced by chemical carcinogens, it may be possible to test 
the efficacy of oncolytic adenoviruses in immunocompetent mice and examine 
the role of both neutralising antibody and cytotoxic T lymphocytes responses in 
viral replication and cytolysis.
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4.1.2. Selective replication of an E lB deficient adenovirus in mouse 
epidermal cell lines.
The use of replicating oncolytic adenoviruses in cancer therapy may be 
potentially advantageous if we can selectively target tumour cells leaving 
normal tissue unaffected. The ElB  deleted adenovirus, Onyx-015, may be 
therapeutically useful in the treatment of a wide range of tumours since p53 
abnormalities are very common in human cancer. However, little is known of 
the effect of the immune system on this virus. To develop an 
immunocompetent mouse model to test this virus we tested a wide range of 
mouse epidermal cells of known p53 sequence and function to determine if we 
could demonstrate the same selectivity for p53(-) mouse cells. The cell lines 
B9, A5, PDVc57 which have point mutations in p53 and the cell line SN161 
which has an 8bp deletion in p53 all show positive CPE’s and hexon protein 
staining. In contrast, the cell lines PI, P6, CarB with wild type p53 did not. 
This was very encouraging as it showed that the same selectivity was 
demonstrable in mouse tissue. Interestingly the cell line C5N which has normal 
p53 sequence and function as determined by G1 arrest in response to radiation, 
also showed good replication. We have proposed that the mechanism for 
replication of Onyx-015 in cell lines with wild type p53 is dependent upon 2 
restriction points- these are the E lA  expression in infected cells and secondly 
the ability for virus to induce S phase cells for virus to replicate. In CarB, there 
is low ElA  expression due to high (|)AP3 (data not shown). In addition, p21 is 
induced which would decrease the number of S phase cells. Therefore, CarB 
has 2 restriction points which will prevent replication. In C5N, we have high 
E lA  expression and also loss of p21 expression at 72 hours post infection.
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Both high E lA  and low p21 would favour efficient viral replication and this 
would account for replication of Onyx-015 in this cell line. In P6, high E lA  
expression occurs as it has a squamous phenotype. This would favour 
replication. However, p21 is induced by Onyx-015 and remains high 
throughout infection. This would reduce S phase cells and therefore restrict 
viral replication.
Northern blot analysis of p21 mRNA expression in C5N , shows that 
the loss of p21 is due to a combination of p53 transcriptional repression and 
also p21 protein degradation. Repression of p53 activity can occur via the large 
ElB 55k protein which binds directly to the N terminal end of p53. This 
protein is absent in Onyx-015 and therefore is not responsible for the repression 
observed. The viral protein E40RF6 is expressed however. This has been 
reported to repress p53 transcriptional activity directly by binding to the C 
terminal end of p53 and causing a conformational change in p53 (Dobner and 
Shenk ,1996). This is the most likely mechanism for p53 transcriptional 
repression and the reduction in p21 mRNA levels seen at 72 hours post 
infection. However, p21 protein degradation also occurs and is probably the 
main mechanism for loss of p21 expression. It has recently been reported that 
p21 is cleaved by caspase activation in apoptosis causing loss of the C terminal 
end of p21 and therefore loss of the nuclear localisation signal (Levkau et 
al,1998). This is not the cause of p21 loss in C5N since there was no evidence 
for apoptosis in this cell line after Onyx-015 infection.(data not shown). 
Recently, it has been shown that overexpression of the cellular factor pl20^'^^ 
leads to stabilisation of p21 protein by a p53 independent post-transcriptional 
mechanism (Fernandes et al,1998). It has also been shown that adenoviral E lA
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can downregulate expression of pl20’^ '^  ^ (Fernandes et al,1997) and therefore 
reduce the half-life of p21 protein. Since E lA  is highly expressed in C5N , 
p i20^^  ^ may be downregulated in C5N leading to reduced stability of p21 
protein. This could also explain why CarB has high p21 expression since ElA  
expression in this cell line is low and we would therefore predict high pl20^'^^ 
expression. However, this hypothesis would not explain why P6 has high p21 
expression since E lA  in this cell line is high and is comparable to that of C5N. 
We are currently looking at the expression of pl20^'^^ in these cell lines.
In conclusion, we have shown that the E lB  deleted adenovirus, Onyx- 
015, will selectively replicate in mouse cell lines with mutant p53 as described 
for human tumour cell lines by Bischoff et al, 1996. In addition however we 
have also shown that some cell lines with wild type p53 (C5N) will also 
support replication and this was dependent upon 2 factors- the E lA  expression 
after infection and also the p21 level after infection.
4.1.3. In Vivo Studies.
Based on the in vitro data on mouse epidermal cell lines, 2 squamous 
epidermal cell lines were chosen for in vivo testing- B9 and PDVc57. 
Subcutaneous tumours were formed and then injected with either Ad2 or Onyx- 
015 virus. In both cases, virus injection was able to cause delayed growth of 
tumours and the results were statistically significant. Survival of mice injected 
with virus was also improved. Evidence for viral replication was detected by in 
situ hybridisation in all Ad2 and Onyx injected tumours but was found to be 
less than in human tumour xenografts(BICR16). The reduced replication in the 
mouse epidermal xenografts is compatible with that seen in vitro where we
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showed a x25-x50 fold reduction in viral replication. This would account for 
the fact that we do not see tumour regression as with human tumour xenografts, 
only delayed growth. In addition, the doubling time of mouse epidermal cells is 
12 hours compared to BICR16 which is 24 hours. Thus, absence of tumour 
regression is due to more rapidly growing tumours and reduced efficiency of 
replication in mouse epidermal xenografts. Nevertheless, we are able to show a 
therapeutic effect which enables us to examine the role of the immune system 
in a syngeneic host.
To examine the role of the immune system and viral replication, 
PDVc57 xenografts were formed in their syngeneic host C57bl/6 mice. Again 
virus injected tumours grew more slowly than control(PBS) injected tumours 
for both Ad2 and Onyx-015 indicating that virus was having a therapeutic 
effect. However, when in situ hybridisation was carried o u t , none of the Onyx 
injected tumours showed evidence of virus and only 2 of the Ad2 injected 
tumours showed evidence of virus. This was evidence that virus replication was 
repressed in the syngeneic host and suggested that virus elimination by the 
immune system occurred. The reason for efficacy may be due to the initial viral 
replication before the immune system cleared the virus, or may be due to an 
immune effector cell infiltration into the tumour. At present there is no 
commercially available antibody to detect mouse CD4 or CD8 lymphocytes and 
therefore the question of increased immune infiltration remains unanswered. 
However, using this model we can now examine the effect of 
immunosuppressants e.g. cyclophosphamide, dexamethasone on viral 
replication and tumour growth. Smith et al,1996 showed that 
cyclophosphamide and deoxyspergualin(DSG) given at time of first adenovirus
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injection in C57bl mice prevented the formation of neutralising antibody and 
permitted an effective second administration of vector. We would therefore 
expect improved efficacy in the syngeneic host on giving immunosuppresants. 
Humoral immunity could also be suppressed by using y interferon and IL-12 
(Yang et al,1995) or by using viruses with non crossreactive serotypes 
(Mastrangeli et al,1996). Alternatively the virus could be encapsulated with 
poly (lactic-glycolic) acid copolymer (PLGA) as reported by Pekarck et al,1994. 
This has been reported to reduce immunogeneicity to second adenoviral 
inoculation in vivo (Beer et al,1998). The cytotoxic T cell response has also 
been suppressed in mice following CTLA Ig administration(Kay et al,1995). 
All of these experiments are currently planned for use in the immunocompetent 
mouse model.
4.2. MECHANISTIC STUDIES ON THE SELECTIVE REPLICATION 
OF ONYX-015 IN P53(-) CELL LINES.
We have shown that Onyx-015 virus infects the ovarian carcinoma cell 
lines A2780 and Cp70 with comparable infectivities using a lacZ reporter virus 
and also E lA  immunofluorescent assay. When infected with the ElB deleted 
adenovirus, Onyx-015, burst assays and hexon protein assay show that 
replication is more productive in the cell line Cp70 which has non-functional 
p53. Very poor replication is found in A2780 which has wt p53 sequence and 
function. Studies by Kim et al (unpublished results) on p53 mutant 
transfectants of A2780 showed increased replication when A2780 was stably
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transfected with a dominant negative p53 gene. This confirmed fhe selectivity 
for virus replication for cells with non-functional p53.
The cell line Cp70 is a cisplatin resistant derivative of A2780 and has 
non-functional p53. Several other cisplatin resistant variants of A2780 have 
been established in the laboratory (MCP1-MCP9) . As with Cp70, these cells 
show increased replication with Onyx-015 in comparison to A2780 by a factor 
of x5-xl0 ( Kim et a l ,unpublished results).
Recent papers by Ridgeway et al,1997 and by Goodrum and 
Ornelles,1997 and by Hall et al,1998 have suggested that replication of ElB 
deleted adenoviruses showed no correlation to p53 status, although in all three 
papers the p53 function of the cell lines used was not tested. Goodrum 
suggested that replication was cell cycle dependent and that replication was 
more productive if cells were in S phase of the cell cycle and that this was 
independent of p53 status. Hall showed that viral induced cell death was more 
efficient in wild type p53 cell lines but failed to show the mechanism of cell 
death,i.e. apoptosis or viral replication. To further examine the mechanism of 
replication of Onyx-015 in Cp70 (non-functional p53) versus A2780 
(functional p53) , we hypothesised replication was dependent on the host 
infected cells being in S phase. This effect may be mediated by the E lA  gene 
by interacting with the Rb/E2F complex causing release of free active E2F and 
Gl-S phase progression as described previously. For cells with non-functional 
p53 (Cp70) , this would allow viral DNA replication to occur resulting in 
cytolysis. For cells with functional p53 (A2780) , it is known that E lA  can 
induce p53 and that this can lead to apoptosis (Lowe and Ruley,1993) . The 
mechanism as to how ElA  induces p53 has only recently been shown to
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involve the tumour suppressor p l9 ^ ^  (de Stanchina et al,1998) which is able 
to prevent mdm2 degradation of p53. This induction of p53 by pl9  may result 
in cell cycle arrest or apoptosis and this would prevent S phase cells increasing 
on viral infection. Since Onyx-015 retains the E lA  gene we may expect p53 
mediated arrest or apoptosis to occur. However, the situation is complicated by 
the fact that Onyx-015 retains the E1B19K gene which produces a protein 
which is anti-apoptotic (Debbas and White,1993). Figure 53 illustrates the 
model suggested.
To test this hypothesis, cell cycle analysis was done at a MOI of 
lOOpfu/cell using pulse BrdU labelling to measure cells in S phase. Both 
A2780 and Cp70 were infected with Ad2 or Onyx-015 over a 72 hour period 
and the percentage S phase , 01 and G2 phase cells estimated at 0, 24 or 72 
hours post infection. For Cp70 , there is an increase in S phase cells with both 
Ad2 and Onyx-015. For A2780, Ad2 infection causes the percentage of S 
phase cells to increase greatly at 24 hours and then reduce whereas with Onyx- 
015 the percentage of cells in S phase changes very little on infection. This 
picture would fit exactly with our hypothesis. Western blotting showed that the 
increase in S phase cells was not dependent upon a change in Rb 
phosphorylation from the hypophosphorylated form to the hyperphosphorylated 
form. However, using bandshift assays for E2F, we have shown that both Ad2 
and Onyx-015 cause E2F induction to occur. E2F exists in 5 different subtypes, 
E2F1-5 (Moberg et al,1996). The most abundant subtype in cells tends to be 
E2F4 and this is the most potent transcriptional activator after E2F-1. With 
Cp70, E2F4/5 both increase with Ad2 or Onyx-015 infection. This would cause 
S phase progression allowing viral replication and cytolysis to occur. With
110
A2780, E2F4/5 induction also occurs with Ad2. However, it was unexpected to 
see an even greater increase with Onyx-015 which was inconsistent with our 
hypothesis and also did not agree with the cell cycle data. It has recently been 
reported that overexpression of E2F-1 can cause apoptosis alone (Hung et 
al,1997) , but particularly in the presence of high p53 levels (Wu et al,1994). 
Therefore high E2F and p53 levels seen in A2780 may cause apoptosis and this 
would explain our cell cycle data and also the poor replication seen in A2780.
We have shown by cell morphology, PARP cleavage and TUNEL 
staining that Onyx-015 causes apoptosis in A2780. Indeed if a clonogenic 
survival curve is carried out on A2780 over a range of MOI, we see a decrease 
in cell survival with increasing MOI, an effect due to apoptosis not viral 
replication. Western blotting for p53 protein shows a large increase with Onyx- 
015 . This effect of ElB deleted adenoviruses in cells with wt p53 has already 
been reported by Grand et al,1994. We have shown that p53 induced by Onyx- 
015 is not transcriptionally repressed by E40RF6 as reported by Dobner and 
Shenk,1996 since mRNA levels of p21, bax and mdm2 levels do not decrease 
post infection. We have also shown by immunoprécipitation studies that p53 
levels remain high due to inhibition of mdm2 mediated degradation and we 
have suggested that this effect is most likely mediated by adenoviral E lA  
induction of p l9  as reported by de Stanchina,1998. Thus high levels of 
functional p53 are induced in the cell line A2780. This , together with the high 
E2F induction would cause apoptosis. Analysis of the Bcl-2 group of proteins 
has shown that apoptosis involves a reduction in bclxL and an increase in bax 
protein. In comparison, cell line Cp70 showed no evidence of apoptosis and
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there was no change in the Bcl2 family of proteins. This would fit very well 
with the pathway we have hypothesised.
We then asked the question why apoptosis should occur in A2780 since 
Onyx-015 still retains the E1B19K gene which has been reported to be a potent 
inhibitor of bax. When we examined the levels of ElB19kDa protein expressed 
in Cp70 and A2780 at the same MOI, we were surprised to see high levels in 
Cp70 and very low levels in A2780. Thus apoptosis in Cp70 would be 
inhibited by the ElB19kDa protein allowing cells to remain in S phase and 
allowing viral replication and cytolysis to occur. In contrast, ElB19kDa protein 
is weakly expressed in A2780 and therefore p53/E2F induced apoptosis is 
allowed to proceed. This difference in ElB19kDa protein levels suggested that 
E1B19K gene may be downregulated in A2780 , possibly by p53 itself. To 
examine this further we are currently screening wild type p53 and mutant p53 
tumour cell lines to determine whether or not mutant p53 cells have high 
ElB19kDa protein expression and wild type p53 cells have low ElB19kDa 
protein expression.
4.3. COMBINATIONAL THERAPY OF ONYX-015 WITH DNA 
DAMAGING AGENTS CISPLATIN AND RADIATION.
It has already been reported by Sanchez-Prieto et al,1998 that E lA  has 
an anti tumour effect in vivo and that this is dependent on E lA  binding to 
p60,pl05,pl07.Similarly Shisler et al,1996 has reported that the induction of 
susceptibility to TNF by E lA  is also dependent on binding of E lA  to either 
pl05(Rb) or p300 to induce DNA synthesis. E lA  transfected into tumour cells
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also increases the cytotoxicity to DNA damaging agents. Lowe and Ruley,1993 
reported that fibroblasts with wtp53 transfected with ElA  were sensitised to 
both radiation and cytotoxics. This was a p53 dependent mechanism since null 
p53 fibroblasts were not sensitised. The mechanism of signaling of E lA  to p53 
has only recently been described and involves induction of pl9 as described 
above (de Stanchina et al,1998). pl9 inhibits mdm2 degradation of p53 thus 
leading to p53 stabilisation. This mechanism is distinct from the pathway of 
p53 activation and stabilisation by DNA damaging agents which involves the 
phosphorylation of serine 15 of p53. This prevents mdm2 interacting with p53. 
Because these mechanisms of p53 stabilisation are different ,synergy should 
exist between ElA  and DNA damaging agents. However, Sanchez-Prieto et 
al,1995 have also showed increased sensitivity to DNA damaging agents 
irrespective of p53 status. In addition. Brader et al,1997 showed increased 
sensitivity to various cytotoxics in the cell line SKOV3(mutant p53) transfected 
with ElA. They hypothesised that this may be due to a decrease in p i85 levels 
though Frisch et al, 1991 showed that increased sensitivity also occurred in cells 
which did not express p i85.
Since Onyx-015 retains the E lA  gene we hypothesised that this virus 
may also increase the sensitivity to cytotoxics and to radiation in both wt and 
mutant p53 cell lines. We again used the paired cell lines A2780 and Cp70 to 
determine this. In A2780, we found increased cytotoxicity to radiation but the 
effects were additive in nature, not synergistic as one might have predicted. 
With cisplatin, antagonism occurred at 24 hours but additivity at 72 hours 
exposure to virus. This could be explained in terms of the p21 levels in A2780 
in which we found induction of p21 at 24 hours with a reduction at 72 hours.
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The induction of p21 at 24 hours is p53 mediated and would result in G1 arrest 
of cells. Since cisplatin is S phase specific agent, it would have less effect at 24 
hours postinfection. As can be seen, p21 levels drop rapidly at 72 hours and 
this would allow more cells to be in S phase and for cisplatin to be more 
effective. The mechanism for p21 reduction at 72 hours may in part be due to 
p53 transcriptional repression by E4orf6 (Dobner and Shenk ,1996). However , 
Northern blot analysis showed no reduction in p21 mRNA levels as was seen in 
C5N mouse epidermal cell line. Therefore in A2780 the main mechanism of 
p21 loss is by post-transcriptional degradation. p21 cleavage has recently been 
reported to occur by caspase activation in apoptosis and this may be the reason 
for the reduction in p21 seen (Levkau et al,1998). In addition, adenoviral ElA  
may be downregulating p i20^ "^  ^ leading to reduced p21 stability. It is also 
known that E lA  can activate the ubiquitin degradation pathway causing 
proteolysis of topoisomerase II(Nakajima et al,1996).
In the cell line Cp70, the cytotoxicity to both cisplatin and radiation is 
increased following infection with Onyx-015 both for 24 hours and 72 hours 
virus exposure. The effects are synergistic which suggests there is an 
interaction between virus and cisplatin or radiation. This interaction may be 
between cisplatin/radiation and the E lA  gene of Onyx-015 . It is possible that 
the E lA  protein induces a reduction in pl85 and therefore increases sensitivity 
to cytotoxics (Brader et al,1997) in infected cells . It would therefore be 
interesting to look at pl85 expression following Onyx-015 infection.
Clinically the combination of virus with DNA damaging agents is 
important. The combination should have greater efficacy than either agent 
alone in tumours with non-functional p53. In addition in tumours which are
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heterogeneous with both wtp53 and mutant p53 cells, Onyx-015 would kill 
mutant p53 cells while chemotherapy/radiation would kill wtp53 tumour cells. 
However, toxicity may also be increased since we have shown that in cells 
with wild type p53, Onyx-015 although not replicating, will induce p53 
mediated apoptosis and this effect is enhanced if combined with chemotherapy 
or radiation. At present use of this virus is confined to intratumoural imjection 
of HNSCC , pancreas, liver métastasés and therefore the local tissue toxicity 
may not be too problematic. However, if systemic administration of Onyx-015 
is given in combination with chemotherapy then there is potential for more 
serious toxicity to occur. Therefore, in vivo toxicity experiments in mice using 
systemic virus delivery and chemotherapy will have to be carried out before 
this therapy enters clinical trials.
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